

CURRICULUM VITAE

Adrienne C. Scheck, Ph.D.

Academic Background

1972-1976	University of Rochester	Awarded B.A. degree in Biology
1976-1980	Rensselaer Polytechnic Institute	Awarded Ph.D. degree in Biology

Professional Background

2021-present	Designated Campus Colleague (Research Scientist), University of Arizona College of Medicine - Phoenix, Phoenix, AZ
2018-2019	Senior Research Scientist, Institute of Molecular Medicine, Phoenix Children's Hospital Research Institute, Phoenix Children's Hospital, Phoenix, AZ
2018-present	Research Associate Professor, U of Arizona College of Medicine, Phoenix, AZ
2017-present	Adjunct Associate Professor, Barrow Neurological Institute of St. Joseph's Hospital and Medical Center, Phoenix, AZ.
2013-2017	Associate Professor, Neuro-Oncology Research, Barrow Brain Tumor Center, Barrow Neurological Institute of St. Joseph's Hospital and Medical Center, Phoenix, AZ.
2011-present	Associate Investigator, Cancer Biology Program, Arizona Cancer Center, University of Arizona, Tucson, AZ
2007-2011	Clinical Faculty, Arizona State University, Tempe, AZ (this designation was discontinued by ASU)
2006-2008	Director, Solid Tumor and infectious Disease Sections, DNA Diagnostic Laboratories, St. Joseph's Hospital and Medical Cent., Phoenix, AZ.
2003-present	Joint Appointment, Neurosurgery Research, Barrow Neurological Institute of St. Joseph's Hospital and Medical Center, Phoenix, AZ.
2002	PathVysion Her-2/neu Training, Vysis Inc.
2001-2006	Chief, Solid Tumor Section, DNA Diagnostic Laboratories, St. Joseph's Hospital and Medical Center, Phoenix, AZ.
1999-2006	Chief, Infectious Disease Section, DNA Diagnostic Laboratories, St. Joseph's Hospital and Medical Center, Phoenix, AZ.
1/25/99	COBAS Amplicor Basic Operator Training, Roche Diagnostics
1999-present	Adjunct Professor, Depart. of Molecular and Cellular Biology, Arizona State U.
1997-present	Adjunct Professor, Department of Biology, Arizona State University
1989-present	Principal Investigator, Neuro-Oncology Research, Barrow Neurological Institute of St. Joseph's Hospital and Medical Center, Phoenix, AZ.
1990-present	Director, <i>Scientific Enrichment Program for Students</i> , Neuro-Oncology Research, Barrow Neurological Institute of St. Joseph's Hospital and Medical Center, Phoenix, AZ.
1986-1989	Research Associate, Memorial Sloan-Kettering Cancer Center, NY, NY
1981-1986	Teaching Assistant, College of Medicine, Pennsylvania State University, The Milton S. Hershey Medical Center, Hershey, PA
1981-1986	Postdoctoral Fellow, College of Medicine, Pennsylvania State University, The Milton S. Hershey Medical Center, Hershey, PA
1976-1980	Teaching Assistant, Rensselaer Polytechnic Institute, Troy, NY
1979-sum	Research Assistant, Rensselaer Polytechnic Institute, Troy, NY
1976	Teaching Assistant, University of Rochester, Rochester, NY

Memberships in Major Professional Societies

American Association for Cancer Research
Society for Neuro-Oncology
International Neurological Ketogenic Society (INKS)

Professional Service

Reviewer for Professional Journals:

Acta Neuropathologica
ASN Neuro
Brain
Brain Pathology
Biotechniques
BMC Cell Proliferation
Cancer
Cancer Genetics and Cytogenetics
Cancer Letters
Cancer Research
Cellular and Molecular Neurobiology
Clinical Cancer Research
European Journal of Clinical Nutrition
Evidence Based Complementary and Alternative Medicine
Genes Chromosomes and Cancer
International Journal of Environmental Research and Public Health
International Journal of Cancer
International Journal of Molecular Sciences
International Journal of Preventive Medicine
Journal of Biomedicine and Biotechnology
Journal of Neuro-Oncology
Journal of Neuroscience Research
Journal of Visual Experimentation (JOVE)
Molecular Cancer Therapeutics
Neuro-Oncology
Neurotherapeutics
Nutrients
Nutrition and Metabolism
Pilot and Feasibility Studies
Public Library of Science One (PloS One)
Radiation Research

Reviewer for books:

Chapter - Homeostatic Control of Brain Function
Chapter - Targeting the Warburg Effect for Cancer Therapy: A Long and Winding Road

Requested Pre-submission Reviews:

KD Cochrane Review for spine and brain tumours requested by Karolis Zienius, Clinical Research Fellow, Edinburgh Centre for Neuro-Oncology, Western General Hospital, Edinburgh, University of Edinburgh, Edinburgh, Scotland

Editorial Board Cancer Genetics and Cytogenetics, 2009 – 2013
 CNS Oncology, 2012 – present
 World Journal of Surgical, Medical and Radiation Oncology, 2012 – present
 Brain Tumors Biology and Therapy 2013 – present
 Journal of Advances in Oncology 2016 – present Brain Tumor Section Editor
 SL Clinical and Medical Oncology 2017 – present
 International Journal of Molecular Sciences 2020 - present

Managing Editor - Intracranial Meningiomas - A Critical Review. Frontiers in Bioscience, May 2009.

Reviewer of Grants

2001 Member, Pathology C Study Section, National Cancer Institute, NIH
American Cancer Society
1994 Ad hoc reviewer, Advisory Committee for Cell Biology
1994 - 1996, Member, Advisory Committee for Cell Biology
1996 - 1997, Member, Advisory Comm. for Cell Cycle and Growth Control
2003 Department of Veterans Affairs, Merit Review
2004 Susan B. Komen Foundation
2012 Auckland Medical Research Foundation
2013 Paracelsus Private Medical University in Salzburg, Austria
2017 Ohio Cancer Research
2019 Children with Cancer UK

American Association for Cancer Research
Education Committee Member 1997-1999

Executive Board/Council Member
Women in Cancer Research

Selection Committee Member
Flinn Scholars Program – 1996-1997
Arizona Rhodes Scholarship - 1997-2002
Arizona State University SOLUR Program - 2004-present

Abstract Reviewer 2014, 2015, 2018, 2019, 2020, 2022 Annual Society for Neuro-Oncology Meeting

Abstract Reviewer 2021 Society for Neuro-Oncology and National Cancer Institute's Joint Symposium:
Targeting CNS Tumor Metabolism

Organizing Committee:

5th Global Symposium on Ketogenic Therapies, 9/20-24, 2016, Banff, Alberta, Canada
8th Global Symposium on Ketogenic Therapies, 9/17-21, 2023, San Diego, CA, USA

Medical Board Advisor – Oncology Specialist – Matthew's Friends Charity, 2015 – present

2016 – PhD Thesis Reviewer – Ms Sujata U. Vaidya, Savitribai Phule Pune University, Pune, India

2017 – PhD thesis advisor – Eric C. Woolf, Awarded PhD from ASU May, 2017

Scientific Committee, 7th Global Symposium on Medical Ketogenic Dietary Therapies, 10/19-23/2021, Brighton, UK (postponed from 2020).

International Neurological Ketogenic Society(INKS) 2020 - present
Executive Committee – Founding Member
Chair, Website Committee

Editor – Special Issue of International Journal of Molecular Sciences (IJMS) - Metabolic Therapies for the Treatment of Cancer

Community Service

Southwest Behavioral Health Services - Board of Directors - 2000-present (President of the Board of Directors - 2007-2009; 2015-2016).

Adult Board Member - Students Supporting Brain Tumor Research Walk-a-Thon 2005 - present

Advisory Council Member: Center for Research in Engineering, Science, and Technology (CREST Paradise Valley Unified School District - 2012 – present

Host and lecturer - BMI at BNI (science summer camp with Arizona Science Center) - 2005 – 2017

Invited Panelist “Women in Stem” Women’s Empowerment Series, YWCA; 9-29-16

Invited Participant – Arizona Innovation Summit 8-14-14

Advisory Board – The Science and Technology Expo, Arizona - Nov. 2010 - 2013

Invited participant ISEF site visit - part of the effort to have the International Science and Engineering Fair to be held in Phoenix in 2013. – May 2009

Co-chairperson - Intel International Science and Engineering Fair - 2005

Honorary Chairperson - Students Supporting Brain Tumor Research Walk-a-Thon 2004

Advisor for Biotechnology Program, Glendale Community College 2002 - present

Design Team Resource, Arizona Bioengineering Collaboration - educational initiative involving the Arizona Science Center - 2001 - 2006

Faculty Member, Project LEAD (Leadership, Education and Advocacy Development - National Breast Cancer Coalition) - Atlanta, GA, 1999

Advisory Council Member: Biotechnology Signature Program, Paradise Valley Unified School District

Advisory Council Member: Flinn Foundation Biotech Project, University of Arizona, Tucson

Industrial Partner, *High Quality Biotechnology On a Shoestring Program* sponsored by the National Association of Biology Teachers (Ms. Margaret Burton, Trevor Browne High School, teacher applicant), 1996-1997.

Invited Participant - Flinn Foundation Meeting on Secondary Education in Arizona, 1994.

Central Arizona Science and Engineering Fair - Frequent Judge - Health and Medicine Division

Invited Participant - Arizona Community Foundation Science Education Discussion Group, 1995.

Reader - *Biology Textbooks*, Recording for the Blind and Dyslexic (national organization based in Princeton N.J.)

Sponsor - Mr. Robert Furlong - Cortez High School, ASBMB High School Teacher Fellowship 1995.

Sponsor - Mr. James Anton - Phoenix Country Day School, ASBMB High School Teacher Fellowship 1990.

Mentor - *Scientific Enrichment Program for Students* - high school and college students 1990 - 2017

Lecturer - *Scientific Enrichment Program for Students* - Cancer Biology Seminar for High School Students 1990 – 2017

Invited Talks and Symposium Participation

5/11/92 Cancer Biology Seminar Series - University of Arizona, Tucson, AZ "*Molecular Biology of Brain Tumors*"

9/17/93 Applications of Molecular Genetics to Medical Practice - Symposium sponsored by Barrow Neurological Institute "*Introduction to Molecular Genetic Techniques*"

1994 Invited Participant - Flinn Foundation Meeting on Secondary Education in Arizona

1995 Invited Participant - Arizona Community Foundation Science Education Discussion Group

4/8/96 Cancer Biology Seminar Series - University of Arizona, Tucson, AZ "*Identification of Genes Involved in Therapy Resistance in Human Malignant Gliomas*".

12/3/96 Zoology Departmental Seminar Series - Arizona State University, Tempe, AZ "*Molecular Analysis of Therapy Resistance in Human Malignant Gliomas*".

2/12/97 Cancer Drug Development in Arizona - Symposium sponsored by the University of Arizona "*Molecular Analysis of Alkylating Agent Resistance in Human Malignant Gliomas*".

8/30/99 Molecular and Cellular Biology Seminar Series - Arizona State University, Tempe, AZ "*Novel Genes Involved in Alkylating Agent Resistance in Human Malignant Gliomas*".

3/4/01 27th Annual Symposium: Breakthroughs in Neuroscience- Neurology/Neuroimaging "*Molecular Biology for the Practice of Neurology and Neuro-Oncology*".

2/26/01 Arizona Cancer Drug Development Meeting – "*Molecular Mechanisms of Therapy Resistance in Human Malignant Glioma*".

7/26/01 Brigham Young University Invited Lecturer – "*Molecular Analysis of Alkylating Agent Resistance in Human Malignant Gliomas*"

3/4/02 28th Annual Symposium: Breakthroughs in Neuroscience- Neurology/Neuroimaging "*Molecular Biology for the Practice of Neurology and Neuro-Oncology*".

9/20/02 National Brain Tumor Foundation Conference – "*Genetic Markers of Brain Tumors*".

3/2/03 29th Annual Symposium: Breakthroughs in Neuroscience- Neurology/Neuroimaging "*Molecular Biology for the Practice of Neurology and Neuro-Oncology*".

10/7/03 Arizona State University Computational Biology Department - "*Computational Biosciences and Clinically Oriented Research*".

2003 Invited participant: Cancer Therapeutics Platform Retreat, Sponsored by the Flinn Foundation for The Arizona Biosciences Roadmap.

10/10&11/03 Invited participant Arizona Biosciences Leadership Symposium, co-sponsored by the Flinn Foundation and the Arizona Disease Control Research Commission

9/9&10/03 Invited participant Comprehensive Molecular Analysis of Human Gliomas and Medulloblastomas. Sponsored by DHHS, NIH, NINDS, NCI

3/9/04 30th Annual BNI Symposium: Breakthroughs in Neuroscience- Neurology/Neuroimaging – "*Molecular Medicine and Diagnostics in the Genomic Age*"

3/29/04 Neuro-Tumor Club Annual Meeting of the American Association for Cancer Research Satellite Meeting "*Therapy-Related Translocations of Chromosomes 11 and 22 in Recurrent Human Malignant Gliomas*".

9/20/04 Invited Speaker - College of American Pathologist 2004 Annual Meeting "*Molecular Markers for Brain Tumors*"

9/21/04 College of American Pathologist 2004 Annual Meeting Vysis Workshop "*Molecular Markers for Brain Tumors*"

10/13/04 *Invited Speaker - McGarey Physician Study Group Lecture "Molecular Biology from Bench to Bedside: Medicine in the Genomic Era*

3/19 /05 Pacific Southwestern Regional Genetics Seminar "*Molecular Markers for Brain Tumors*".

11/1/07 Downtown Lecture Series – "*Therapy-Related Translocations of Chromosomes 11 and 22 in Recurrent Human Malignant Gliomas*"

2/17/07 Brain Tumors; Confronting the Challenge Together – "*Research Update*" The Brain Tumor Society Symposium

3/17/07 Workshop on Malignant Gliomas - Panel Discussion

2/16/08 Students Supporting Brain Tumor Research Dinner Dance Keynote Speaker

4/18/08 Invited Speaker, Phoenix Bioscience Summit

- 8/1/08 Invited Speaker, Arizona Science Center Adult's Night Out - Brain Cancer Therapy: A Different Approach
- 11/21/08 University of Arizona Medical School – *“Brain Tumors: Prognosis, Therapies and Therapy Resistance”*
- 3/9/09 Phoenix Children's Hospital Brain Tumor Group *“The Ketogenic Diet and Gliomas: Opportunities to Make Difference”*
- 4/18/09 Invited Speaker annual IVIS® Users Group Meeting – *“Neuro-Oncology Models and Treatment Efficacy”*
- 10/7/10 Invited Speaker, Global Symposium on The Dietary Treatments For Epilepsy And Other Neurological Disorders, Edinburgh, Scotland, UK – *“Insights from Genetic Profiling”*
- 10/11/10 Invited Speaker, University of Wolverhampton, Wolverhampton, UK – *“The Ketogenic Diet for the Adjuvant Treatment of Glioblastomas”*
- 3/27/11 Invited Lecture University of Arizona Cancer Center. *“Metabolic Alteration as an Effective Adjuvant Therapy for the Treatment of Malignant Gliomas”*.
- 7/6-7/12 Invited Speaker, RSG1 Glucose Transporter Conference *Orlando, Florida, “Altering Cellular Metabolism: An Effective Adjuvant Therapy for the Treatment of Malignant Glioma”*
- 9/24/12 Invited Speaker, Overlook Medical Center, Summit, NJ, *“Metabolic Alteration as an Effective Adjuvant Therapy for the Treatment of Malignant Gliomas”*
- 10/24/12 Invited Speaker, PerkinElmer Revolutionaries for Global Health Summit, *“In vivo Ketogenesis Models of Brain Tumors”*
- 3/11/13 Invited Speaker, Phoenix Children's Hospital Neuroscience Grand Rounds *“Metabolic Alteration as an Effective Adjuvant Therapy for the Treatment of Malignant Gliomas”*
- 7/10-12/13 Invited Speaker, British Neuro-Oncology Society 2013 Annual Meeting, Durham University, UK *“Preclinical Studies of the Ketogenic Diet for the Adjuvant Treatment of Malignant Glioma”*
- 7/15/13 Invited Speaker, South of England Brain Tumour Alliance, Portsmouth, UK *“Metabolic Alteration as an Adjuvant Therapy for the Treatment of Malignant Glioma”*
- 9/14/13 Invited Speaker, Barrow Brain Tumor Symposium, *“Ketogenic Diet for Metabolic Modulation as an Adjuvant Therapy for Gliomas”*
- 3/12/14 Invited Speaker, Registered Dietician's Day – *“Metabolic Alteration: A New Take on Cancer Therapy”*
- 4/14/14 Invited Speaker, Phoenix Children's Hospital Neuroscience Grand Rounds *“Update on the use Metabolic Alteration as an Effective Adjuvant Therapy for the Treatment of Malignant Gliomas”*
- 5/26/14 Invited Speaker, Alberta Children's Hospital for Developmental Neurosciences Grand Rounds *“Metabolic Alteration as an Effective Adjuvant Therapy for the Treatment of Malignant Gliomas”*
- 5/26/14 Invited Participant and Speaker, Cancer Metabolism Workshop, Alberta Children's Hospital for Developmental Neurosciences *“Metabolic Alteration for Malignant Gliomas”*
- 5/29/14 Invited Speaker/Participant, Blue Sky Meeting - Ketones and Astronaut Safety, Performance, and Resilience *“Mechanisms of Action of the Unrestricted Ketogenic Diet – Lessons Learned From Cancer Therapy Research”*
- 10/10/14 Invited Speaker, Professional Session - Global Symposium on The Dietary Treatments For Epilepsy And Other Neurological Disorders, Liverpool, UK – *“Utilisation of the KD as an Adjuvant to Radiotherapy”*
- 10/11/14 Invited Speaker, Family Session - Global Symposium on The Dietary Treatments For Epilepsy And Other Neurological Disorders, Liverpool, UK – *“Utilisation of the KD as an Adjuvant to Radiotherapy”*
- 10/13/14 Invited Speaker, Imperial College, London – *“The Ketogenic Diet as an Adjuvant Therapy for Malignant Brain Tumors”*
- 10/29/14 Invited Speaker, 2014 Cancer Research, Discovery and Therapeutics virtual conference, labroots & bioconference live. A live video streamed webinar.
<https://www.youtube.com/watch?v=xBy3ylQjhMw>

- 10/31/14 Invited Speaker, American Institute for Cancer Research Annual Research Conference, Washington, DC – *“The Ketogenic Diet for the Adjuvant Therapy of Malignant Glioma”*
- 11/7/14 Invited Speaker, Flex Conference, Health Occupations Students of America (HOSA) – *“Neuro-Oncology Research”*.
- 11/9/14 Invited Speaker, Barrow Brain Tumor Symposium, *“Ketogenic Diet and Metabolic Modulation as Adjuvant Therapy for Gliomas”*
- 10/15/15 Invited Speaker, National Brain Tumor Society 2015 Scientific Summit, *“The Ketogenic Diet for the Treatment of Brain Tumors: a Pluripotent Therapy Whose Time Has Come”*
- 10/22/15 Invited Speaker, Central Academy Nutrition and Dietetics meeting, *“Altering Metabolism for Cancer Therapy: Food for Thought”*
- 11/7/15 Invited Speaker, Barrow Brain Tumor Symposium, *“Metabolic Therapy for the Adjuvant Treatment of Malignant Gliomas”*
- 11/28-29/15 Invited Speaker, 3rd International Congress on Integrative Medicine *“The Ketogenic Diet as an Adjuvant Treatment for Glioma”*. Fulda, Germany
- 12/3/15 Invited Speaker, Imperial College, London *“The Ketogenic Diet for the Treatment of Brain Tumors: a Pluripotent Therapy Whose Time Has Come”*.
- 1/29/16 Invited Speaker, 1st Annual Conference on Nutritional Ketosis and Metabolic Therapies, Tampa, FL, *“The Ketogenic Diet as an Adjuvant to Standard of Care”*.
- 4/1/16 Invited Speaker, University of Virginia Cancer Center Seminar Series, *“Metabolic Therapy for the Adjuvant Treatment of Malignant Gliomas”*.
- 4/29/16 Invited Speaker 2016 Biennial Oncology Nutrition DPG Symposium *“Altering Metabolism for Cancer Therapy: Food for Thought”*.
- 9/22/16 Invited Speaker, 5th Global Symposium on Ketogenic Therapies, Banff, Alberta, Canada, *“Dietary Therapies for Brain Cancer: A Clinical Trials Update”*.
- 9/22/16 Introduction and Session Moderator, Brain Tumors, 5th Global Symposium on Ketogenic Therapies, Banff, Alberta, Canada.
- 11/23/16 Invited Speaker International Symposium: Cancer Metabolism: mechanisms and treatment strategies, Frankfurt, Germany, *“Altering Metabolism for the Therapy of Glioma and Other Cancers”*.
- 1/20/17 Keynote Speaker, Students Supporting Brain Tumor Research/U of Arizona Medical School Gala dinner, *“Altering Metabolism for the Therapy of Brain Tumors and Other Cancers”*.
- 2/2/17 Invited Speaker, 2nd Annual Conference on Nutritional Ketosis and Metabolic Therapeutics 2/1/17-2/4/17, Tampa FL, *“The Ketogenic Diet for Glioma: Fighting the Perfect Storm”*.
- 2/10/17 Invited Speaker, Neuroscience Grand Rounds, Phoenix Children’s Hospital, *“The Ketogenic Diet for Glioma: Fighting the Perfect Storm”*.
- 2/25/17 Invited Speaker, 5th Annual Barrow Neuro-Oncology Symposium, 2/24-25, 2017, Phoenix, AZ, *“Tumor Metabolism – Glioma’s Achilles Heel”*.
- 3/11/17 Invited Speaker, Spring Summit on Ketogenic Diet Therapies for Epilepsy and other Neurologic Disorders, Phoenix Children’s Hospital and The Charlie Foundation, March 11-12, 2017, Scottsdale, AZ, *“The Ketogenic Diet as an Adjuvant Therapy for Brain Tumors: An Idea Whose Time Has Come”*.
- 4/1/17 Invited Speaker, 4th International Congress on Integrative Medicine, April 1-2, 2017, Fulda Germany. *The Ketogenic Diet as an Adjuvant Treatment for Glioma: Fighting the Perfect Storm*.
- 4/14/17 Keynote Speaker, Mercy Health Hauenstein Neurosciences Ketogenic Diet Therapies Conference and Open House, Grand Rapids, MI. *“The Ketogenic Diet for Glioma – a Pluripotent Therapy for the Adjuvant Treatment of Gliomas”*.
- 5/1/17 Invited Speaker, 2017 Nutrition & Health Conference: State of the Science & Clinical Applications, May 1-3, 2017, Phoenix, AZ. *“The Ketogenic Diet as an Adjuvant Therapy for Cancer”*.
- 5/18/17 Invited Speaker, Providence Saint Joseph Medical Center, Burbank, CA, *“Ketogenic Metabolic Therapy for Brain Tumors: Fighting the Perfect Storm”*.

- 8/5/17 Invited Speaker, 2017 Patient and Family Conference, Redefining Survivorship through Science, Clinical Innovation and Technology, ABTA, August 4-5, 2017, Chicago, IL, *"Altering Metabolism for Brain Tumor Therapy: Food for Thought – The Research"*.
- 9/7/17 Invited Speaker, KetoKademy, Las Vegas, NV, *"Ketogenic Metabolic Therapy for Brain Tumors: Fighting the Perfect Storm"*.
- 9/15-16/17 Invited Participant, WhatIFF Symposium for Pediatric Brain Tumor Research, *"Metabolic Ketosis for the Treatment of Pediatric Brain Tumors"*.
- 9/21/17 Invited Speaker, Rethinking Cancer 2017, Paris, France, *"Experience in Solid Tumors"*.
- 11/2-4/17 Invited Speaker and Participant, James S. McDonnell Foundation - Ketogenic Diet Workshop. Tarrytown, NY. *"Food for Thought: The Ketogenic Diet for Brain Tumor Therapy."*
- 11/9/17 Invited Speaker, RDs In Practice: Advancing Practice in Pediatric Nutrition, Children's Hospital of Orange County, CA, *"Ketogenic Diet Therapies for Brain Cancer: The Utility of Metabolic Ketosis"*.
- 11/12/17 Invited Speaker, Live it to Lead it HCF Seminar, Carlsbad, CA *"Therapeutic Use of the Ketogenic Diet for Cancer."*
- 11/16/17 Invited Speaker, Annual Meeting of the Society for Neuro-Oncology Education Day, *"Ketogenic Diet in the Management of Brain Tumors."*
- 11/16/17 Invited Speaker, Annual Meeting of the Society for Neuro-Oncology, Town Hall Meeting: Hot Topics in Neuro-Oncology, *"Integrative Medicine: Nutritional Intervention as an Adjuvant Therapy."*
- 1/9/18 Invited Speaker, University of Alabama, Birmingham, AL. *"Pluripotent Effects of Metabolic Ketosis for the Adjuvant Treatment of Brain Tumors"*.
- 1/26/18 Invited Speaker, Radiation Therapy Oncology Group Meeting, *"Therapeutic Mechanisms of the Ketogenic Diet With and Without Radiation: Lessons Learned From Rodent Models"*.
- 5/25/18 Invited Speaker, 1st Global Symposium Ketogenic Diet and Metabolic Therapies. South Tyrol, Italy. *"Ketogenic diet as adjunctive therapy for malignant brain cancer"*.
- 8/4/18 Invited Speaker, ABTA 2018 National Patient & Family Conference, Chicago, IL, *"Altering Metabolism for Brain Tumor Therapy: Food for Thought"*.
- 8/17/18 Invited Speaker, Emerging Science of Carbohydrate Restriction Conference, Ohio State University, *"Diet as Adjunctive Therapy for Malignant Brain Cancer: Mechanisms Beyond Glucose Reduction"*.
- 9/20/18 Invited Speaker, KetoKademy, Dallas, TX, *"Ketogenic Metabolic Therapy for Brain Tumors: Fighting the Perfect Storm"*.
- 11/27/18 Invited Speaker, Central Arizona Academy of Nutrition and Dietetics, *"Metabolic Ketosis as Adjunctive Therapy for Malignant Brain Cancer"*.
- 1/31-2/3/19 Invited Speaker, 3rd Annual Metabolic Health Summit, Long Beach, CA., *"Metabolic Ketosis as Adjunctive Therapy for Malignant Brain Cancer: Mechanisms Beyond Glucose Reduction."*
- 9/13-14/19 Invited Speaker, 2019 Summit on Ketogenic Diet Therapies, Phoenix, AZ. *"Metabolic Ketosis for the Adjuvant Treatment of Cancer"*.
- 11/5/19 Invited Speaker, Caris Life Sciences, Phoenix, AZ. *"Translational Studies of Malignant Brain Tumors"*.
- 10/19-23/21 Invited Speaker, 7th Global Symposium on Medical Ketogenic Dietary Therapies, Brighton, UK. *"Utilisation for Brain Tumours - Evidence from the Laboratory"*.

Lectures and Education

- 11/19/90 Lecturer, Arizona State University, Tempe, AZ *"Molecular Biology of Human Malignant Brain Tumors"*.
- 10/17/91 Grand Rounds- Barrow Neurological Institute *"Molecular Biology of Human Gliomas"*.
- 1/7/93 Neurobiology Lecture Series - Barrow Neurological Institute *"Molecular Studies of Human Malignant Gliomas"*.

7/8/94 Grand Rounds- Barrow Neurological Institute "*Molecular Biology of Human Gliomas - an Update*".

10/29/99 Lecturer, Grand Canyon University – "*Chemotherapy Resistance in Human Brain Tumors*".

4/20/01 Grand Rounds - Barrow Neurological Institute - "*Molecular Diagnosis of Gliomas*".

9/21/01 Lecturer, Grand Canyon University – "*Molecular Analysis of Human Malignant Brain Tumors: Translation of the Results to the Clinic*".

5/28/03 Lecturer, Neurosurgery Resident's Review – "*Molecular Biology of Brain Tumors*".

9/24/03 Lecturer, Glendale Community College – "*Molecular Analysis of Human Malignant Brain Tumors - Biotechnology in Medicine*".

1/15/04 Arizona State University Associated Students for Biotechnology "*Molecular Analysis of Human Malignant Brain Tumors: Biotechnology in Medicine*".

3/22/04 Barrow Neurological Institute Neuroscience Lecture Series "*Molecular Biology of Brain Tumors*".

6/9/04 Arizona State University West Bridges Program "*Molecular Analysis of Human Malignant Brain Tumors: Biotechnology in Medicine*".

6/22/04 Barrow Neurological Institute Brain Tumor Support Group "Update on Brain Tumors".

9/28/04 Lecturer, Glendale Community College – "*Clinical Applications of Biotechnology*".

1/21/05 Community College Curriculum Meeting Invited Speaker – "*The Job of a Research Technician*".

2/22/05 Barrow Neurological Institute Brain Tumor Support Group "*Research Update*".

7/1/05 Lecturer, Arizona State University West – "*Biotechnology in Medicine: Molecular Analysis of Human Brain Tumors*".

9/30/05 Lecturer, Glendale Community College – "*Molecular Analysis of Human Malignant Brain Tumors: Biotechnology in Medicine*".

6/5/06 Barrow Neurological Institute Neuroscience Lecture Series – "*Understanding Outcomes for Oligodendroglial Tumors*".

11/3/06 Lecturer, Glendale Community College – "*Molecular Analysis of Human Malignant Brain Tumors: Biotechnology in Medicine*".

11/4/06 1st Annual ASU-BNI Neuroscience Symposium – "*Therapy-Related Translocations of Chromosomes 11 and 22 in Recurrent Human Malignant Gliomas*".

11/7/06 Spirit of the Senses – "*Genetics in Medicine - Do you Have to Study for Gene Test?*".

1/25/07 Lecturer, Barrow Neurology Resident Lecture – "*DNA Repair*".

5/1/07 High Tech University – "*You CAN Do It (and it's fun)*".

11/29/07 Lecturer, Glendale Community College – "*Molecular Analysis of Human Malignant Brain Tumors: Biotechnology in Medicine*".

1/24/08 Barrow Neurological Institute Board "*Translational Brain Tumor Research and the Scientific Enrichment Program for Students*".

3/27/08 Barrow Neurosurgical Nurse Education "*So THAT'S What You Do With the Stuff: Studies in Neuro-Oncology*".

12/5/08 Lecturer, Glendale Community College – "*Molecular Analysis of Human Malignant Brain Tumors: Biotechnology in Medicine*".

12/8/08 Lecturer, Arizona State University Neuroscience Course – "*Brain Tumors*".

3/26/09 Lecturer, Neurology Residents BNI/SJHMC – "*Molecular Biology of Gliomas - Therapy*".

4/23/09 Lecturer, Neurology Residents BNI/SJHMC – "*Molecular Biology of Gliomas - Introduction*".

4/09 Invited Speaker – Cholla Middle School Career Day

8/6/09 Lecturer, Trauma Residents SJHMC – "*Molecular Medicine*".

12/4/09 Lecturer, Glendale Community College – "*Preclinical Studies of Novel Therapies and the Molecular Analysis of Human Malignant Brain Tumors*".

3/24/10 Invited Speaker, AZ Science Center Adult Lecture Series – "*Personalized Medicine*".

6/5/10 Invited Speaker, AZ Science Center – Biobuzz – "*Human Cloning*".

8/6/10 Lecturer Trauma Residents SJHMC - *Molecular (Personalized) Medicine*.

10/20/10 Lecturer for the Introductory Course for the Interdisciplinary Graduate Program in Neuroscience. "*Brain Tumors*".

12/3/10	Lecturer, Glendale Community College – <i>“Preclinical Studies of Novel Therapies and the Molecular Analysis of Human Malignant Brain Tumors”</i> .
3/1/11	Invited Speaker ASU SOLUR Seminar <i>“Mentoring - Responsible Conduct in Research”</i> .
4/19/11	BNI Neuroscience Lecture Series <i>“Altering Cellular Metabolism: An Effective Adjuvant Therapy for the Treatment of Malignant Glioma”</i> .
5/25/11	Invited lecture Arizona State University Biodesign Lecture Series: <i>“Brain Tumors 101”</i> .
8/8/11	Neuro-psychology Graduate student Tour/Lecture.
11/4/11	Neuro-psychology Graduate student Tour/Lecture.
3/13/12	Invited lecture Arizona State University, Molecular and Cell Biology, <i>“Brain Tumors 101”</i> .
6/26/12	BNI Brain Tumor Support Group <i>“Research Update”</i> .
8/9/12	Lecturer, Trauma Residents SJHMC - <i>Molecular (Personalized) Medicine</i> .
11/29/13	Arizona Science Center- <i>“Sugar is Bad, Fat is Good: A New Take on Cancer Therapy”</i>
12/6/13	Lecturer, Glendale Community College – <i>“Preclinical Studies of Novel Therapies and the Molecular Analysis of Human Malignant Brain Tumors”</i> .
10/28/14	Lecturer, Molecular and Cellular Biology, ASU <i>“Brain Tumors”</i> .
12/4/14	Lecturer, Glendale Community College, <i>“Preclinical Studies of Novel Therapies and the Molecular Analysis of Human Malignant Brain Tumors”</i> .
2/19/15	Lecturer, BCH462: General Biochemistry, <i>“Altering Metabolism for the Treatment of Brain Tumors”</i> .
9/29/15	<i>Barrow Neurological Institute Neuroscience Lecture Series “Altering Metabolism to Improve the Current Standard of Care for Cancer”</i> .
12/18/15	Lecturer, Glendale Community College, <i>“Preclinical Studies of Novel Therapies and the Molecular Analysis of Human Malignant Brain Tumors”</i> .
12/8/16	Lecturer, Glendale Community College, <i>“Altering Metabolism for the Therapy of Glioma and Other Cancers”</i> .
12/7/17	Lecturer, Glendale Community College, <i>“Cancer – The Perfect Storm”</i> .
2/19/18	Students Supporting Brain Tumor Research <i>“Ketogenic Therapy for Glioma: Food for Thought”</i> .
7/17/18	Institute for Molecular Medicine Research – New Medical Fellows Orientation
10/9/18	Invited Speaker, Mayo Clinic Brain Tumor Support Group, <i>“Ketogenic Metabolic Therapy for Brain Tumors: Fighting the Perfect Storm”</i> .
12/6/18	Lecturer, Glendale Community College, <i>“Cancer – The Perfect Storm”</i> .
2/4/19	Phoenix Children’s Hospital Neuroscience Conference – <i>“Metabolic Ketosis for the Adjuvant Treatment of Brain Tumors”</i> .
4/23/19	7 th PCH Research Day - Gene expression biomarkers for predicting response to abemaciclib in medulloblastoma cells
4/23/19	7 th PCH Research Day - The ketone body β -hydroxybutyrate acts as an epigenetic modifier and increases radiation-induced DNA damage in diffuse intrinsic pontine glioma
8/9/19	BNI at PCH retreat, Phoenix, AZ <i>“Metabolic Therapy for the Adjuvant Treatment of Pediatric CNS Tumors”</i> .
2/28/20	Lecturer, Glendale Community College <i>“Cancer: The Perfect Storm”</i>

Honors Awarded

2015, Most Influential Woman of the Year in Scientific Research, *Continental Who’s Who*.
 2014, Women of Distinction
 2013, 50 Most Influential Women in Arizona Business
 2013, AZ Business Magazine Healthcare Leadership Award, Researcher Finalist
 1998, YWCA Tribute to Women - Scientist/Researcher

PUBLICATIONS

Poster Presentations

- Wigdahl BL, Scheck AC, DeClercq E and Rapp F. Analysis of latent herpes simplex virus type 1 genome in human cells. Sixth Cold Spring Harbor meeting on Herpesviruses, Cold Spring Harbor Laboratory, New York, August 31-September 5, 1982, p. 6.
- Scheck AC, Wigdahl B and Rapp F. Herpes simplex virus type 1 (HSV-1) transcription during establishment of virus latency in vitro. Abstracts Ann. Meeting Amer. Soc. Microbiol., p. 224, 1984.
- Scheck AC, Wigdahl B, DeClercq E and Rapp F. Prolongation of herpes simplex virus (HSV) latency in vitro: Use of combined acyclovir and interferon treatment. American Society for Virology, July 22-26, 1984, Madison, WI, p. 29.
- Scheck AC, Wigdahl B, DeClercq E and Rapp F. Expression of the herpes simplex virus type 1 (HSV-1) genome during establishment of in vitro virus latency using combined nucleoside analogue and interferon treatment. Ninth International Herpesvirus Workshop, Seattle, Washington, August 24-29, 1984, Seattle, WA, p. 30.
- Scheck AC, Wigdahl B and Rapp F. Activation of latent herpes simplex virus in vitro. American Society for Virology, July 21-25, 1985, Univ. of New Mexico, Albuquerque, New Mexico.
- Chou TC, Kong XB, Scheck AC, Fanucchi MP, Watanabe KA, Fox JJ and Price R. Incorporation and metabolism of 2'fluoro-5- substituted arabinosyl pyrimidines into DNA in herpes simplex virus type 1 (HSV-1) infected and uninfected vero cells. Proc. Amer. Assoc. for Cancer Research, 28:306, 1987.
- Andrews D, Scheck AC, Shapiro JR. Morphological transformation of primary cultures of normal human glial cells with an adenovirus 12-simian virus 40 hybrid virus. Am. Assoc. of Neurol. Surgeons, April 24-28, 1988 Toronto, ON.
- Rosenblum M, Brew B, Cardle K, Scheck AC, and Price RW. Pallidonigral degeneration in AIDS: Implications for HIV- related neuronal damage. IV International Conference on AIDS, June 12-16, Stockholm, Sweden, 1988.
- Rosenblum M, Scheck AC, Cronin K, Khan A, Paul M, Brew B, and Price RW. Dissociation of vacuolar myelopathy and detectable HIV infection of the spinal cord. International Academy of Pathology. Lab. Investigations, 60: 80A, 1989.
- Scheck AC, Moots PL, Mehta BM, Ebrahim SAD, and Shapiro JR. BCNU-Resistant human glioma cells exhibit autocrine regulation of platelet-derived growth factor. J. Cell Biochem. Suppl. 13B, 141, 1989.
- Shapiro JR, Mehta BM, Moots PL and Scheck AC. A minor subpopulation of cells in freshly resected malignant gliomas is BCNU-resistant, secretes PDGF-like peptides and becomes the dominant population after BCNU treatment. 3rd International Workshop on Chromosomes in Solid Tumors, Arizona Cancer Center, Tucson, AZ, February 26-28, 1989.
- Scheck AC, Heston WDW and Shapiro JR. Expression of platelet-derived growth factor, ornithine decarboxylase, and the multi-drug resistance gene locus in BCNU-resistant human glioma cells. Proc. Am. Assoc. Cancer Research, 30: 65, 1989.
- Shapiro JR, Mehta BM, Fiola M, Moots PL and Scheck AC. A minor subpopulation of cells in freshly resected malignant gliomas is BCNU-resistant, secretes PDGF-like peptides and becomes the dominant population after BCNU treatment. J. Neuro-Oncology 7: S26, 1989.
- Shapiro JR, Mehta BM, Fiola M, Moots PL, and Scheck AC. Intrinsically chemo- and radio-resistant subpopulations identified in freshly resected human gliomas become the dominant population in recurrent tumor samples. Neurology, 40(Suppl 1): 395, 1990.
- Scheck AC, Mihara Y and Shapiro JR. Regional heterogeneity in human malignant gliomas occurs in anaplastic astrocytomas as well as glioblastomas multiforme. Proc. Am. Assoc. Cancer Res. 31: 306, 1990.

- Shapiro JR, Scheck AC, Mehta BM, Moots PL and Fiola MR. Minor subpopulation of intrinsically chemoresistant and radioresistant cells in primary gliomas become the dominant population in recurrent tumors. J. Cancer Res. Clinical Onc. Supp. 116:1135, 1990.
- Scheck AC, Mihara Y, Beikman MK, Korn CM and Shapiro JR. Regional analysis of human malignant gliomas: Expression of genes mapped to chromosomes 7 and 22. Neurology, 41:158, 1991.
- Scheck AC, Beikman MK, Korn MC and Shapiro JR. Regional analysis of genes potentially involved in resistance to BCNU in human malignant gliomas. Proc. Am. Assoc. Cancer Research, 32:358, 1991.
- Shapiro JR and Scheck AC. Cytogenetic, biochemical and molecular analyses of primary and recurrent tumors following adjuvant therapy. Fourth International Workshop on Chromosomes in Solid Tumors.
- Shapiro JR and Scheck AC. Analysis of primary and recurrent tumors: Cytogenetic, biochemical and molecular correlates of *in vitro* and *in vivo* BCNU therapy. Ninth International Conference on Brain Tumors, Asilomar, CA 1991.
- Shapiro JR, Scheck AC, Berens ME and Joy AM. Molecular biological techniques identify aberrant expression of growth factors in BCNU-resistant cell populations in whole tissue samples from patients treated for malignant gliomas. Neurology, 1992.
- Scheck AC, Rhodes SN, Berens ME and Shapiro JR. Analysis of the epidermal growth factor receptor in primary and recurrent human malignant gliomas. Proc. Am. Assoc. Cancer Research 33:82, 1992.
- Berens ME, Rief MD, Coons SW, Haskett D, Scheck AC and Shapiro JR. Recurrent human astrocytomas show elevated expression of epidermal growth factor receptor. Proc. Am. Assoc. Cancer Research 33:82, 1992.
- Shapiro JR and Scheck AC. Molecular cytogenetic and molecular analyses of primary and recurrent gliomas. Proc. Am. Assoc. Cancer Research 34:82, 1993.
- Golfinos JG, Norman SA, Coons SW, Spetzler RF and Scheck AC. Expression of the genes encoding myelin basic protein and proteolipid protein in glial tumors. Proc. Am. Assoc. Cancer Research 35:551, 1994.
- Norman SA, Shapiro JR and Scheck AC. Expression of protein phosphatase type 1 in human malignant gliomas. Proc. Am. Assoc. Cancer Research 35:551, 1994.
- Scheck AC, Norman SA and Shapiro JR. Identification of genes involved in BCNU resistance in human malignant gliomas using differential mRNA display. Proc. Am. Assoc. Cancer Research 36:326, 1995.
- Norman SA, Golfinos JG, and Scheck AC. Expression of a receptor protein tyrosine phosphatase (RPTP β) in human malignant gliomas. Proc. Am. Assoc. Cancer Res., 36:524, 1995.
- Norman SA, Hoelzinger DB, Rhodes SN, Dicken RJ, Shapiro JR, and Scheck AC. Identification of genes involved in BCNU resistance in human malignant gliomas using differential mRNA display. Differential Display and Related Techniques for Gene Discovery Cold Spring Harbor Laboratory, Oct. 6-9, 1996, pg 67.36:326, 1995.
- Scheck AC, Shapiro JR, Ballacer C, Kohlke E, Rhodes SN, Sinnott HA, Norman S.A., and Bohnert A. Clonal analysis of human malignant glioma cells selected for resistance to BCNU. Proc. Am. Assoc. Cancer Research, 37:338, 1996.
- Norman SA, Saito H, Hoelzinger DB and Scheck AC. Expression of an alternatively spliced RPTP ζ/β in a subset of human malignant gliomas. Proc. Amer. Assoc. Cancer Res. 37: 36, 1996.
- Furlong RJ, Scheck AC, Shapiro JR, and Coons SW. Molecular alterations in primary and recurrent human malignant glioma. Proc. Am. Assoc. Cancer Research, 38:544, 1997.
- Scheck AC, Norman SA, Shapiro JR and Rhodes SN. Molecular analysis of alkylating agent resistance in human malignant glioma. 12th International Conference on Brain Tumor Research and Therapy, J Neuro-Oncology 35:S40, 1997.
- Shapiro JR, Scheck AC, Schrock E, and Reid T. Genetic and molecular analysis of twelve primary/recurrent pairs of gliomas. 12th International Conference on Brain Tumor Research and Therapy. J Neuro-Oncology 35:S41, 1997.

- Scheck AC, Norman SA, Rhodes SN and Shah R. Alternate mechanisms of alkylating agent resistance in human malignant gliomas. *Proc. Am. Assoc. Cancer Research*, 39:658, 1998.
- Scheck AC, Rhodes SN, Shapiro JR, Rojanala S, Furlong RJ, Steinway ML. Novel mechanisms of 1,3-bis(2-chloroethyl)-1-nitrosourea resistance in human malignant gliomas. *Proc. Am. Assoc. Cancer Research*, 40:427, 1999
- Rojanala S, Scheck AC, Pero RS, Shapiro JR. Amplification of chromosome 22 fragments region q11.21-q13.2 in recurrent tumors. *Proc. Am. Assoc. Cancer Research*, 41:782, 2000.
- Scheck AC, Armijo B, Pero RS and Shapiro JR. Chromosome 22 fragments in BCNU resistant human malignant gliomas. *Proc. Am. Assoc. Cancer Research*, 41:783, 2000.
- Scheck AC, Pero RS and Husu EN. Expression of the tumor suppressor gene RIG (regulated in glioma) in BCNU resistant human malignant glioma cells. *Proc. Am. Assoc. Cancer Research*, 41:867, 2000.
- Norman S, Scheck A and Braman J. Analysis of *TP53* mutations in human malignant glioma. *Oncogenomics: Dissecting Cancer Through Genomics Research*, *Nature Genetics*, 27(4):76. DOI:10.1038/87226, 2001.
- Scheck AC, Pero RS, and Armijo BS. Identification of differentially expressed genes in therapy resistant cells from primary and recurrent human malignant gliomas. *Neuro-Oncology* 2:293, 2000.
- Scheck AC, Sen G, Pero RS, and Armijo BS. Identification of Differentially Expressed Genes Mapped to Chromosome 22 in Human Malignant Gliomas. *Proc. Am. Assoc. Cancer Research*, 42:4627, 2001
- Ivanov AI, Pero RS, Scheck AC, Romanovsky AA. Expression of genes encoding prostaglandin E₂ synthesis in lipopolysaccharide fever. *FASEB J.* 15: A1105, 2001.
- Ivanov AI, Pero RS, Scheck AC, Romanovsky AA. Lipopolysaccharide fever: Different febrile phases are characterized by different expression patterns. *Soc. for Neuroscience*, 2001.
- Scheck AC, Pero RS, Armijo BS and Hank N. Identification of Genes That Are Differentially Expressed And/or Represented in Cells from Primary and Recurrent Human Malignant Gliomas. *Assilomar Conference*, 2001.
- Sen G, Rao D, Preul MC and Scheck AC. Nucleotide excision repair and BCNU resistance in glioblastoma multiforme, *Annual Meeting of the American Association of Neurological Surgeons*, 2001.
- Scheck AC, Hank NC, Pero RS and Kertesz B. Treatment of human malignant gliomas with temozolomide selects for a genetically different population of cells than those selected by 1,3-bis(2-chloroethyl)-1-nitrosourea. *Proc. Am. Assoc. Cancer Research*, 43:4588, 2002.
- Sawyer TF, Pero RP, Scheck AC. Differential Expression of the Gene Encoding Fibronectin Precursor in Cell from Primary and Recurrent Human Malignant Gliomas. *Proc. Am. Assoc. Cancer Research*, 43:5480, 2002.
- Scheck AC, Pero RS, and Hank, NC. Molecular cytogenetic and differential gene expression analyses of BCNU resistant cells from primary and recurrent tumors. *Assilomar Conference, Neuro-Oncology* [serial online],: Doc. C71, September 19, 2002 URL: <http://neuro-oncology.mc.duke.edu>.
- Perry KB, Scheck AC, Clark WD, and Hank NC. *In vitro* screening for anticancer activity of flavanoid-rich extracts derived from the mature roots of *Scutellaria baicalensis* on human malignant brain tumor cells. *Arizona American Society of Plant Biologist Conference*, 2003.
- Scheck AC, Hank NC, Pero RS. Translocation of 22q13.1-13.31 and Chromosome 11 in Recurrent Human Malignant Glioma Correlates with Resistance to 1,3-bis(2-chloroethyl)-1 Nitrosourea. *Proc. Amer Assoc Cancer Res* (2nd ed), 44:R5545, 2003.
- Perry KB, Scheck AC, Clark WD, and Hank NC. *In vitro* screening for anticancer activity of flavanoid-rich extracts derived from the mature roots of *Scutellaria baicalensis* on human malignant glioma cells. *Neuro-Oncology* 5(4): 305, 2003.

- Scheck AC, Hank NC, Kertesz B, Stone JF and Kilbourn JL. Over-representation of chromosome region 22q12.3-13.31 and translocation of chromosomes 11 and 22 in recurrent human malignant glioma correlates with resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea. *Neuro-Oncology* 5(4): 314, 2003.
- Ashby LS, Coons SW, Puschel JK, Scheck AC and Shapiro WR. Oligomatosis cerebri and leptomeningeal oligomatosis as causes of death in patients with oligodendroglial tumors. *Neuro-Oncology* 5(4): 330, 2003.
- Puschel JK, Ashby LS, Shapiro WR, Coons SW, Karis JP, Smith KA and Scheck AC. Redefining multicentric and multifocal gliomas in the age of magnetic resonance imaging. *Neuro-Oncology* 5(4): 341, 2003.
- Hendricks WP, Pfisterer WK, Nieman RA, Hank NC, Preul MC, Scheck AC. Characterization of molecular, genetic, and biochemical profiles associated with meningioma progression and recurrence. *Proc. Amer Assoc Cancer Res* 45:1165, 2004.
- Kilbourn JL, Hendricks WP, Scheck AC. Molecular analysis of alpha B-crystallin in human malignant glioma cell populations *Proc. Amer Assoc Cancer Res* 45:2263, 2004.
- Scheck AC, Hank NC, Chavez C. Therapy-related translocations of chromosomes 11 and 22 in recurrent human malignant gliomas. *Proc. Amer Assoc Cancer Res* 45:1212, 2004.
- Ivanov AI, Steiner AA, Scheck AC, and Romanovsky AA. Expression of Eph receptors and their ligands, ephrins, during lipopolysaccharide fever in rats. *Physiol Genomics* 2005 (DOI 10.1152/physiolgenomics.00043.2004).
- Pfisterer WK, Hendricks W, Barnhard M, Coons SW, Scheck AC, Nieman RA and Preul MC. 1H Spectroscopic Analysis of Meningiomas Demonstrates Specific Metabolic Changes Correlating with More Aggressive Clinical Features. *Amer. Assoc. of Neurological Surgeons (AANS)*. May 2004.
- Pfisterer WK, Hank NC, Hendricks WP, Puschel J, Coons SW, Preul MC and Scheck AC. Diagnostic and/or Prognostic Significance of Genetic Regional Heterogeneity in Meningiomas *Amer. Assoc. of Neurological Surgeons (AANS)*. May 2004.
- Hendricks WP, Pfisterer WK, Nieman RA, Coons SW, Scheck AC and Preul MC. Characterization of Biochemical Profiles Associated with Meningioma Progression and Recurrence. *AANS/CNS Satellite Symposium*. October 2004.
- Hendricks WP, Pfisterer WK, Nieman RA, Coons SW, Ramsey KA, Stephan DA, Scheck AC and Preul MC. Characterization of Molecular Profiles Associated with Meningioma Progression and Recurrence. *AANS/CNS Satellite Symposium*. October 2004.
- Hendricks WP, Pfisterer WK, Nieman RA, Ramsey KE, Coons SW, Stephan DA, Scheck AC and Preul MC. Molecular and Biochemical Analyses of Alanine Metabolism Across Meningioma Grade and Recurrence. *AANS/CNS Satellite Symposium*. October 2004.
- Hendricks WP, Pfisterer WK, Nieman RA, Coons SW, Preul MC and Scheck AC. Characterization of molecular, genetic, and biochemical profiles associated with meningioma progression and recurrence. *Society for Neuro-Oncology Annual Meeting*. November 2004.
- Hendricks WP, Coons SW, Preul MC, Ramsey KE and Scheck AC. Global expression profiles predict meningioma recurrence and reveal novel pathways leading to aggressive phenotypes: a new clinical model of meningioma aggression. *Annual Meeting of the American Association For Cancer Research*. March 2005.
- Winkler JA, Hendricks WP, Johnson D, Xia J and Scheck AC. Global microRNA expression analysis in human malignant glioma cells reveals novel miRNA-mediated therapy-resistance mechanisms. *Annual Meeting of the American Association For Cancer Research*. March 2005.
- Hendricks WP, Coons SW, Scheck AC, Ramsey KE, Stephan DA and Preul MC. Gene Expression Profiling and Immunohistochemical Screening Establish a Novel Tool for Clinicopathological Management of Meningiomas. *Annual Meeting of the American Association of Neurological Surgeons*. June 2005.

- Hendricks WP, Coons SW, Scheck AC, Ramsey KE and Preul MC. Immunohistochemical Screening Based on Gene Expression Profiles Predictive of Meningioma Recurrence. @ World Federation of Neuro-Oncology and European Association for Neuro-Oncology Meeting. May 2005.
- Scheck AC, Panyon L, Hank N, Martinez G. Specific translocations of chromosomes 11 and 22 in recurrent malignant gliomas. World Federation of Neuro-Oncology and European Association for Neuro-Oncology Meeting. May 2005.
- Shapiro WR, Ashby LS, Puschel JK, Scheck AC, Coons SW, Lowe L, Green, Factors Predicting survival in patients with oligodendroglial tumors: evaluation of histopathology, molecular genetics, neuroimaging and therapy in 210 patients. Neuro-Oncology 7:323, 2005
- Ashby LS, Puschel JK, Scheck AC, Coons SW, Shapiro WR, Lowe L, Green SB. Prognostic factors for patients with newly diagnosed low grade tumors: molecular genetics, histopathology, and neuroimaging. Amer. Acad. of Neurology May 2005.
- Ashby LS, Puschel JK, Scheck AC, Coons SW, Shapiro WR: Prognostic factors for patients with newly diagnosed low-grade oligodendroglial tumors: molecular genetics, histopathology, and neuroimaging. J. Clin Oncol, Suppl 23: 114s, 2005.
- Bredel M, Bredel C, Juric D, Duran G, Yu RX, Harsh GR, Vogel H, Recht LD, Scheck AC, Sikic BI. TNFAIP3/A20 as a potential regulator of NF- κ B-mediated resistance to O⁶-alkylating chemotherapy in glioblastoma multiforme AACR Meeting Abstracts, Apr 2006; 1054.
- Finch A, Panyon L, Schilling R, Meuliet EJ, Biggs C, Martinez G, Schneider D, Scheck AC. The Effects of Radiation On Cells From Glioblastoma Multiforme: Chromosomal Translocation t(11;22) and Growth Inhibition. Annual Meeting of the American Association for Cancer Research. April 2006.
- Mitchell M, Eggink LL, Scheck AC. Protein analysis of primary and recurrent human malignant gliomas. Annual Meeting of the American Association for Cancer Research April 2006.
- Panyon L, Meuliet EJ, Schilling R, Biggs C, Martinez G and Scheck AC. Translocation of chromosomes 11 and 22 t(11;22) in recurrent human malignant glioma may be related to radiation therapy. Annual Meeting of the Society for Neuro-Oncology 2006.
- Mitchell M, Eggink LL, Scheck AC. Protein analysis of primary and recurrent human malignant gliomas. Annual Meeting of the Society for Neuro-Oncology 2006.
- Shapiro WR, Ashby LS, Puschel, JK, Scheck AC, Coons SW, Lowe K, Green SB: Understanding outcomes for oligodendroglial tumors: Oligodendroglioma (O), oligoastrocytoma (OA) and their anaplastic counterparts (AO, AOA). Neurology 66 (Supl 2): A399-400, 2006.
- Mitchell MR, Scheck AC. Proteomic analysis of therapy resistance in primary and recurrent human gliomas. Annual Meeting of the American Association for Cancer Research, 2007.
- Fouerman P, Hendricks WP, Stafford P, Coons SW, Scheck AC. Gene Expression Analysis of Primary and Recurrent Meningiomas. Society for Neuro-Oncology, 2007.
- Sankar T, Assina R, Scheck AC, Hooper JK, Eggink LL, Coons SW, Preul MC. Immunotherapy with a synthetic peptide improves response to radiotherapy in a murine glioma model. 42nd annual Congress of the Canadian Neurological Sciences Federation, June 21, 2007.
- Sankar T, Assina R, Scheck AC, Eggink LL, Hooper JK, Coons SW, Preul MC. Use of a Synthetic Peptide Mimetic of Macrophage Activating Factor for Glioma Immunotherapy. Annual meeting of the Amer Assoc Neurological Surgeons, 2008.
- Fouerman P, Fenton K, Flores K, Stafford P, Nakaji P, Scheck AC. Molecular Genetic Analysis for Improved Prognostication of Meningiomas. Neuro-Oncology 10:864, 2008
- Smith R, Smith K, Biggs C, Scheck AC. Resistance of Brain Tumor Cells to Gamma Knife Radiosurgery. Annual Meeting of the American Association for Cancer Research, 2008.
- Abdelwahab MG, Kim D-Y, Milligan H, Rho JM, Scheck AC. The Ketogenic Diet as an Adjuvant Therapy for Malignant Gliomas. Neuro-Oncology 10:785, 2008.
- Julia A. Mackey, Phillip Stafford, Stan Iwai, X. James Xia and Adrienne C. Scheck. The Potential Role of miRNAs in Therapy Resistant Brain Tumors. Annual Meeting of the American Association for Cancer Research, 2009.

- Abdelwahab MG, Kim D-Y, Milligan H, Kushchayev SV, Martirosyan NL, Rho JM, Preul MC, Scheck AC. The Ketogenic Diet as an Adjuvant to Current Treatments for Malignant Gliomas. Annual Meeting of the American Association for Cancer Research, 2009.
- Abdelwahab MG, Kushchayev SV, Martirosyan NL, Sankar T, Scheck AC, Eggink LL, Hooper KJ, Preul MC. Administration of a Synthetic Peptide Mimetic of Macrophage Activating Factor Improves Response to Radiotherapy in a Murine Glioma Model. Annual Meeting of the American Association of Neurological Surgeons, 2009.
- Abdelwahab MG, Kushchayev SV, Martirosyan NL, Sankar T, Scheck AC, Eggink LL, Hooper KJ, Preul MC. Administration of a Synthetic Peptide Mimetic of Macrophage Activating Factor Improves Response to Radiotherapy in a Murine Glioma Model. XIV World Congress of Neurological Surgery, 2009.
- Abdelwahab MG, Stafford P, Kim D-Y, Preul MC, Rho JM, Scheck AC. Influence of the Ketogenic Diet on the efficacy of radiation and chemotherapy for the treatment of malignant glioma. American Association for Cancer Research Special Conference on Metabolism and Cancer, 2009.
- Kushchayev SV, Abdelwahab MG, Kushchayev Y, Sankar T, Ruolan L, Fu-Dong S, Scheck AC, Eggink LL, Hooper KJ, Preul MC. A Novel Synthetic Peptide Mimetic Activates Macrophage/Microglia in a Murine Glioblastoma Model. Annual Combined meeting of Society for Neuro-Oncology and American Association of Neurological Surgeons CNS division, 2009.
- Abdelwahab MG, Kushchayev SV, Kushchayev Y, Sankar T, Ruolan L, Fu-Dong S, Scheck AC, Eggink LL, Hooper KJ, Preul MC. Influence of a Synthetic Peptide Mimetic of Macrophage Activating Factor in Response to Radiotherapy in a Murine Glioma Model. Annual Combined meeting of Society for Neuro-Oncology and American Association of Neurological Surgeons CNS division, 2009.
- Moore NZ, Ryan RWJ, Sankar T, Fenton K, Kanberoglu B, Scheck AC, Smith KA, Nakaji P, Debbins J, Spetzler RF, Preul MC. Markers of clinically aggressive tumors *in vivo* that provide a resection advantage. Annual meeting of the Soc. of Neuro-Oncology, 2009.
- Moore NZ, Ryan R, Sankar T, Fenton K, Kanberoglu B, Debbins J, Scheck AC, Spetzler RF, Preul MC. 3D 1H-Magnetic Resonance Spectroscopy Integrated into a Standard Neurosurgical Image Guidance System - Providing a Resection Advantage and Determining Biochemical Markers of Clinically Aggressive Meningiomas *In Vivo*. Annual meeting of the Amer Assoc of Neurological Surgeons, 2009.
- Zobenica N, Ryan R, Sankar T, Fenton K, Kanberoglu B, Debbins J, Karis JP, Smith KA, Scheck AC, Nakaji P, Spetzler RF, Preul MC. In Vivo 1H-Magnetic Resonance Spectroscopy to Determine Biochemical Markers of Clinically Aggressive Meningiomas Annual Meeting of the Amer Assoc of Neurological Surgeons, 2009.
- Sankar T, Zobenica N, Ashby L, Scheck AC, Shapiro WR, Shapiro J, Wilson J, Smith K, Spetzler RF, Preul MC. MRI Volumetric Extent of Contrast Enhancement and Resection in Oligodendroglial Tumors. Annual Meeting of the Amer Assoc of Neurological Surgeons, 2009.
- Sankar T, Eschbacher J, Coons SW, Scheck AC, Nakaji P, Spetzler RF, Preul MC. In Vivo Hand-held Confocal Microscopy for Neurosurgery - Results in an Experimental GBM Model. Annual Meeting of the Amer Assoc of Neurological Surgeons, 2009.
- Yadav A, Renfrow J, Scholtens D, Xie H, Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe P, Das S, Scheck AC, Kessler JA, Soares B, Sikic BI, Harsh GR, Bredel M. Monosomy 10 dysregulates EGFR signaling in glioblastomas. SNO 2009.
- Bredel M, Scholtens D, Harsh GR, Bredel C, Chandler JP, Renfrow J, Yadav A, Vogel H, Scheck AC, Tibshirani R, Sikic BI. Model of a cooperative genetic landscape in gliomas. SNO 2009.
- Bredel M, Yadav A, Renfrow J, Alvarez AA, Scholtens D, Lin D, He X, Chandler JP, Bredel C, Phillips HS, Vogel H, Robe P, Mobley, Scheck AC, Sikic BI, Aldape KD, Chakravarti A, Harsh GR. IKBA is an EGFR-regulating tumor suppressor in glioblastomas. SNO 2009.
- Scheck AC, Abdelwahab MG, Stafford P, Kim D-Y, Fenton K, Kushchayev SV, Preul MC, Rho JM. The ketogenic diet as an adjuvant therapy for malignant gliomas. *Neuro-Oncology* 11(5):601, 2009.

- Scheck AC, Abdelwahab MG, Stafford P, Kim DY, Preul MC, Rho JM. Molecular Analysis of the Ketogenic Diet As An Adjuvant Therapy For Malignant Gliomas. AACR Genetics of Brain Tumors Meeting 2009.
- Smith KA, Scheck AC, Smith R. A new *in vitro* assay using Gammaknife radiosurgery on cells from primary and recurrent GBMs to detect the development of radiation resistance in recurrent tumors. International Gamma Knife Meeting, Greece.
- Pfisterer WK, Nieman RA, Scheck AC, Coons SW, Spetzler RF, Preul MC. Using *ex vivo* proton magnetic resonance spectroscopy to reveal associations between biochemical and biological features of meningiomas. *Neurosurg Focus* 28(1):E12, 2010.
- Scheck AC, Abdelwahab MG, Stafford P, Kim D-Y, Fenton K, Iwai S, Preul MC, Rho JM Mechanistic studies of the ketogenic diet as an adjuvant therapy for malignant gliomas. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 16-21; Washington, DC. Philadelphia (PA): AACR; Abstract 638.
- Lusis EA, Stuart JE, Scheck AC, Coons SW, Lai A, Perry, Gutmann DH. Identification of Gene Markers Associated with Aggressive Meningioma by Filtering Across Multiple Sets of Gene Expression Arrays. Society for Neuro-Oncology 2010.
- Martirosyan NL, Cavalcanti DD, Eschbacher JM, Delaney P, Abdelwahab MG, Scheck AC, Nakaji P, Spetzler RF, Preul MC. Use of Indocyanine Green Near-Infrared Laser Confocal Endomicroscopy *In Vivo*: Potential to Intraoperatively Detect the Boundary of Infiltrative Tumor. *Neurosurgery*. 67(2):562, August 2010.
- Fenton K, Abdelwahab MG, Stafford P, Rho JM, Preul MC, Scheck AC. Ketogenic diet as an adjuvant therapy to radiation and the effects on SAPK/JNK protein expression. Society for Neuro-Oncology In: *Neuro Oncol* 12(suppl 4): iv86-iv99, 2010.
- Bredel M, Yadav A, Renfrow J, Scholtens D, Bredel C, Chandler J, Tagge M, Lukac P, Robe P, Vogel H, Scheck AC, Aldape K, Chakravarti A, Harsh GR. American Brain Tumor Association Young Investigator Award : NFKBIA Deletion in Glioblastoma Multiforme Annual Meeting of the American Association of Neurological Surgeons, 2010.
- Abdelwahab MG, Fenton KE, Stafford P, Eschbacher J, Lynch A, Preul MC, Scheck AC. Efficacy of KetoCal® as an Adjuvant Therapy for Malignant Gliomas. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, Florida. Philadelphia (PA): Abstract 624.
- Fenton KE, Abdelwahab M, Scheck AC. Effect of the ketogenic diet on protein expression of the JIP scaffold proteins. Society for Neuro-Oncology, *Neuro Oncol* (2011) 13 (suppl 3): iii69-iii72 Abstract MP-08.
- Noel M, Woolf E, Smith R, Castillo-Rojas P, Sorenson S, Smith S, Scheck AC. Gamma Knife™ treatment of cells from primary and recurrent glioblastoma: analysis of resistance. Society for Neuro-Oncology, *Neuro Oncol* (2011) 13 (suppl 3): iii127-iii133.
- Abdelwahab MG, Fenton KE, Preul MC, Rho JM, Lynch A, Stafford P, Scheck AC. The Ketogenic Diet is an Effective Adjuvant to Radiation Therapy for the Treatment of Malignant Glioma. Annual Meeting of the American Association of Neurological Surgeons, April 2012.
- Woolf EC, Abdelwahab MG, Fenton K, Stafford P, Pruel MC, Rho JM, Lynch A, Scheck AC. Mechanistic analysis of the ketogenic diet versus KetoCal® as adjuvant treatments for malignant glioma. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL: Abstract 3217.
- Scheck AC, Woolf EC, Turner G, Kodibagkar VD, Shankar RV, Preul MC, Abdelwahab MG, Charlton J. Adjuvant use of the ketogenic diet for the treatment of malignant brain tumors inhibits cyclooxygenase-2 expression and reduces tumor-associated edema. Third International Symposium: Dietary Therapy for Epilepsy & Other Neurological Disorders meeting - Chicago, IL 9/19/12 - 9/21/12.
- Scheck AC, Stafford P, Hughes A, Cichacz Z, Coons SW, Johnston SA. Immunosignaturing for the diagnosis and characterization of human brain tumors Society for Neuro-Oncology *Neuro Oncol* (2012) 14 (suppl 6): vi91-vi100 OM-40.

- Woolf E, Abdelwahab MG, Turner G, Preul MC, Lynch A, Rho JM, Scheck AC. Metabolic alteration as an adjuvant therapy for the treatment of malignant glioma: Effects on tumor edema. *Neuro-Oncology* 14:vi25–vi37, 2012 doi:10.1093/neuonc/nos222 Abstract ET-50.
- Woolf EC, Turner G, Preul MC, Liu Q, Scheck AC. Analyzing the response to metabolic therapy in a mouse model of malignant glioma using multimodality imaging. *Journal of Nuclear Medicine*, published on January 25, 2013 as doi:10.2967/jnm542abs Abstract 83.
- Woolf EC, Stafford P, Abdelwahab MG, Fenton K, Preul MC, Scheck AC. The ketogenic diet potentiates radiation therapy in a mouse glioma model: Effects on inflammatory pathways and reactive oxygen species. Annual Meeting of the American Association for Cancer Research April 6-10, 2013, Washington, DC.
- Woolf EC, Liu Q, Turner G, Abdelwahab MG, Preul MC, Scheck AC. Modulation of inflammatory pathways using metabolic alteration as an adjuvant therapy in a mouse model of malignant glioma. Inaugural Croucher/AACR Summer Course in Cancer Biology, Hong Kong, 2013.
- Woolf E, Abdelwahab MG, Charlton JA, Liu Q, Turner G, Fenton, KE, Preul MC, Scheck AC. The Ketogenic Diet Alters Angiogenic Processes and Edema in a Mouse Model of Malignant Glioma. *Society for Neuro-Oncology Neuro Oncol* (2013) 15 (suppl 3):iii37-iii61. Abstract ET-099.
- Woolf EC, Charlton JA, Liu Q, Turner G, Preul MC, Scheck AC. Metabolic therapy reduces expression of PECAM-1/CD31 and decreases peritumoral edema in a mouse model of malignant glioma. Annual Meeting of the American Association for Cancer Research April 5-9, 2014, San Diego, CA.
- Zieman G, Dardis C, Gomes A, Scheck A, Eschbacher J, Ashby L. Predicting Progressive Gangliogliomas: Early Identification Of Those At Risk In A Sample Of 156 Consecutive Patients Treated at The Barrow Neurological Institute. *American Academy of Neurology*, April 26-May 3, 2014.
- Renda L, Honea N, Woolf EC, Ashby LS, Dardis C Scheck AC. The Effects of a Ketogenic Diet on Quality of Life and the Growth of Brain Tumors. 4th Global symposium for Dietary Therapies for Epilepsy and other Neurological Disorders for Health Care Professionals October 7-10, 2014, Liverpool, UK.
- Woolf EC, Curley KL, Vatsa R, Charlton JA, Woodrow CJ, Scheck AC. The Ketogenic Diet Reduces Carbonic Anhydrase 9 and Alters the Expression of Proteins Involved with Glioma Growth and Progression in Hypoxic Conditions. *Society for Neuro-Oncology Neuro Oncol* (2014) 16:v79-95. Abstract ET-65. *Neuro-Oncology*, Volume 16, Issue suppl_5, November 2014, Page v93, <https://doi.org/10.1093/neuonc/nou255.62>
- Zieman G, Dardis C, Gomes A, Scheck AC, Eschbacher J, Coons S, Ashby L. Ganglioglioma in children; identification of cases at risk of death due to progression following initial surgery. *Society for Neuro-Oncology Neuro Oncol* (2014) 16:v66-74. Abstract ED-39. *Neuro-Oncology*, Volume 16, Issue suppl_5, November 2014, Page v74, <https://doi.org/10.1093/neuonc/nou253.39>
- Johnson JL, Woolf E, Lussier DM, Brooks KS, Blattman JN, Scheck AC. Ketogenic diet enhances immunity to glioblastoma. *Tumor Immunology and Immunotherapy: A New Chapter*, Dec 1-4, 2014, Orlando, FL.
- Pazmandi J, O'Neill K, Scheck AC, Szlosarek P, Woolf EC, Brooks KS, Syed N. The ketogenic diet alters the expression of microRNAs that play key roles in tumor development. Annual Meeting of the American Association for Cancer Research April 18-22, 2015 in Philadelphia, PA.
- Rossi AP, Woolf EC, Brooks KS, Fairres MJ, Scheck AC. The ketone body β -hydroxybutyrate increases radiosensitivity in a mouse glioma cell line *in vitro*. Annual Meeting of the American Association for Cancer Research April 18-22, 2015 in Philadelphia, PA.
- Woolf EC, Johnson JL, Lussier DM, Brooks KS, Blattman JN, Scheck AC. The ketogenic diet enhances immunity in a mouse model of malignant glioma. Annual Meeting of the American Association for Cancer Research April 18-22, 2015 in Philadelphia, PA.

- Renda L, Honea N, Dardis C, Ashby LS, Scheck AC. Clinical effects of a ketogenic diet on brain tumor patients: tumor growth and quality of life. Annual Meeting of the American Association for Cancer Research April 18-22, 2015 in Philadelphia, PA.
- Silva-Nichols HB, Woolf EC, Deleyrolle LP, Reynolds BA, Scheck AC. The ketone body β -hydroxybutyrate radiosensitizes glioblastoma multiforme stem cells. Society for Neuro-Oncology Neuro Oncol (2015).
- Silva-Nichols HB, Rossi AP, Woolf EC, Fairres MJ, Deleyrolle LP, Reynolds BA, Scheck AC. Radiosensitization of glioma cells by the ketone body β -hydroxybutyrate is associated with enhanced cell cycle arrest in the G2/M phase In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; 2016. Abstract 1670
- Rossi AP, Silva-Nichols HB, Woolf EC, Scheck AC. The ketone body β -hydroxybutyrate down regulates c-Myc signaling in a malignant glioma model In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; 2016. Abstract 1022.
- Preston J, Stylianou J, Zeng Q, Glover S, Scheck AC, Woolf EC, O'Neill K, Syed N. The ketogenic diet induces epigenetic changes that play key roles in tumour development. British Neuro-Oncology Society; June 29-July 1, 2016, Leeds, UK. *Neuro-Oncology*, Volume 19, Issue suppl_1, 1 January 2017, Page i28, <https://doi.org/10.1093/neuonc/now292.015>
- Rossi AP, Woolf EC, Silva-Nichols HB, Syed N, Scheck AC. The ketone body β -hydroxybutyrate alters c-MYC signaling in malignant glioma cells. 5th Global Symposium on Ketogenic Diet Therapies, September 20-24, 2016, Banff, Alberta, Canada.
- Woolf EC, Rossi AP, Silva-Nichols HB, Syed N, Scheck AC. β -hydroxybutyrate inhibits histone deacetylase activity and increases radiosensitivity in malignant glioma cells. 5th Global Symposium on Ketogenic Diet Therapies. 5th Global Symposium on Ketogenic Diet Therapies, September 20-24, 2016, Banff, Alberta, Canada.
- Woolf EC, Rossi AP, Silva-Nichols HB, Gardner KD, Syed N, Scheck AC. The ketone body β -hydroxybutyrate inhibits histone deacetylase activity and alters expression of DNA repair proteins in malignant glioma cells. Society for Neuro-Oncology, 2016.
- Crain ID, Elias PS, Chapple K, Scheck AC, Karis JP, Preul MC. 1H-MRS for the differentiation of glioma recurrence from radiation necrosis. AAN April 22-28, 2017 Boston, MA
- Kostelich EJ, Rutter EM, Stepien TL, Anderies BJ, Plasencia JD, Woolf EC, Scheck AC, Turner GH, Liu Q, Frakes D, Kodibagkar V, Kuang Y, Preul MC. Parameter Estimation in a Mathematical Model of Murine Glioma from MR Imaging. 25th Annual Meeting of the International Society for Magnetic Resonance in Medicine (ISMRM). Honolulu, Hawaii, 22-27 April 2017.
- Woolf EC, Rossi AP, Silva-Nichols HB, Gardner KD, Syed N, Scheck AC. β -hydroxybutyrate inhibits histone deacetylase activity and radiosensitizes malignant glioma cells. Annual Meeting of the American Association for Cancer Research; 2017 Apr 1-5; Washington, DC: AACR; 2017. Abstract 1125.
- Woolf EC, Bhattacharya A, Rossi AP, Davidson MM, Syed N, Scheck AC. The ketone body β -hydroxybutyrate chemo- and radio-sensitizes malignant glioma cells by inhibiting histone deacetylase activity and downregulating expression of RAD51. Society for Neuro-Oncology, 2017. *Neuro-Oncology*, Volume 19, Issue suppl_6, November 2017, Page vi83, <https://doi.org/10.1093/neuonc/nox168.340>
- Tzoulis S, Hajji N, Perryman R, O'Neill K, Woolf EC, Scheck AC, Syed N. The ketogenic diet alters the epigenetic landscape of GBM to potentiate the effects of chemo and radiotherapy. Society for Neuro-Oncology, 2017. *Neuro-Oncology*, Volume 19, Issue suppl_6, November 2017, Pages vi96–vi97, <https://doi.org/10.1093/neuonc/nox168.395>
- Dardis C, Renda L, Honea N, Smith K, Nakaji P, Ashby LS, Scheck AC. Therapeutic ketogenic diet (KD) with radiation and chemotherapy for newly diagnosed glioblastoma – preliminary results for NCT02046187. Society for Neuro-Oncology, 2017. *Neuro-Oncology*, Volume 19, Issue suppl_6, November 2017, Page vi4, <https://doi.org/10.1093/neuonc/nox168.011>

- Williams M, Cross H, Jenkinson MD, Martin K, Wood S, Scheck AC, Syed N, O'Neill K, Sheen K, Zabilowicz C, Breen K, Oliver K, Williams E, Johnson M, Fulcher W. The ketogenic diet for patients with brain tumours: Two parallel randomised trials. Annual Meeting of the British Neuro-Oncology Society, 2017. *Neuro-Oncology*, Volume 20, Issue suppl_1, 31 January 2018, Pages i7–i8, <https://doi.org/10.1093/neuonc/nox237.033>.
- Belykh E, Carotenut A, George L, Miller E, Healey DR, Luna-Melendez E, Byvaltsev VA, Staren M, Scheck A, Quarles C, Mehta S, Nakaji P, Preul M. Metabolic and blood-brain-barrier markers for fluorescence -guided surgery: systematic high-resolution microscopy investigation in human relevant experimental gliomas. *Neuro-Oncology*, Volume 20, Issue suppl_6, November 2018, Page vi270, <https://doi.org/10.1093/neuonc/nov148.1123>
- Stafford P, Dardis C, Smith K, Coons SW, Scheck AC. Immunosignature analysis for the prediction of therapy response and tumor recurrence in malignant brain tumors. Arizona Biomedical Research Conference, Phoenix, AZ, 2018.
- Woolf EC, Manhas KR, Healey DR, Blattman JN, Scheck AC. The ketone body β -hydroxybutyrate alters expression of PD-L1 on malignant glioma cells but does not directly affect T cells *in vitro*. American Association for Cancer Research; 2018 Apr 14-18; Chicago, IL. Abstract 2739.
- Rossi AP, Wetmore C, Scheck AC. The ketone body β -hydroxybutyrate acts as an epigenetic modifier and increases radiation-induced DNA damage in diffuse intrinsic pontine glioma. *Neuro-Oncology*, Volume 21, Issue Supplement_2, April 2019, Page ii77, <https://doi.org/10.1093/neuonc/noz036.058>
- Smith K, Conway BN, Smith T, Scheck, AC. Ketogenic Metabolic Therapy Significantly Improves Radiographic and Clinical Response to Salvage Temozolomide in Patients With Recurrent High Grade Gliomas. 24th Annual Meeting of the Society for Neuro-Oncology, 11/20-14, 2019.
- Zeng Q, Stylianou T, Preston J, Glover S, O'Neill K, Woolf EC, Scheck AC, Syed N. The ketogenic diet alters the epigenetic landscape of GBM to potentiate the effects of chemotherapy and radiotherapy, *Neuro-Oncology*, Volume 21, Issue Supplement_4, October 2019, Page iv8, <https://doi.org/10.1093/neuonc/noz167.033>
- Syed N, Zeng Q, Stylianou T, Preston J, Rossi AP, Woolf EC, Scheck AC. Alterations in MicroRNAs Contribute to the Anti-Cancer Effects of Metabolic Ketosis. 5th Annual Metabolic Health Summit, 2020, Long Beach, CA.
- Smith KA, Conway B, Smith T, Scheck AC. Preliminary Results in Patients with High Grade Gliomas When Ketogenic Metabolic Therapy is Added to Standard Therapies. 5th Annual Metabolic Health Summit, 2020, Long Beach, CA.
- Perryman R, Zeng Q, Raha O, O'Neill K, Scheck AC, Syed N. EXTH-41. The microRNA miR-138 may be responsible for some of the effects of metabolic ketosis on malignant glioma, *Neuro-Oncology*, Volume 22, Issue Supplement_2, November 2020, Page ii96, <https://doi.org/10.1093/neuonc/noaa215.395>
- Lane AL, Werner BA, McCarty PJ, Singh IN, Scheck AC, Frye RE. Unique Bioenergetic Profiles of Children with Autism Spectrum Disorder with and without Neurodevelopmental Regression. UMDF Mitochondrial Medicine Symposium, June 8-11, 2022, Phoenix, AZ
- Scheck AC, Werner BA, Almekkawi AK, Sheets R, Lane AL, Singh IN, Frye RE. Mitochondrial Alterations in Malignant Glioma as a Consequence of Therapy. UMDF Mitochondrial Medicine Symposium, June 8-11, 2022, Phoenix, AZ
- Werner BA, Singh IN, Scheck AC, Lane AL, McCarty PJ, McLees SE, Burrows BT, Brown D, Wilfong A, Adelson PD, Frye RE. Mitochondrial Respiration Alterations in Epileptic Foci from Fresh Human Brain. UMDF Mitochondrial Medicine Symposium, June 8-11, 2022, Phoenix, AZ
- Frye RE, Werner BA, McCarty PJ, Lane AL, Scheck AC, Singh IN. Redox Sensitive Autonomous Complex IV Activity in Autism Spectrum Disorder and Control Fibroblasts. UMDF Mitochondrial Medicine Symposium, June 8-11, 2022, Phoenix, AZ.
- Lane AL, Werner BA, McCarty PJ, Singh IN, Scheck AC, Frye RE. Unique Bioenergetic Profiles of Children with Autism Spectrum Disorder with and without Neurodevelopmental Regression. 5th Annual Metabolic Health Summit 5/5 – 8, 2022, Santa Barbara, CA.

- Frye RE, Werner BA, McCarty PJ, Lane AL, Scheck AC, Singh IN. Redox Sensitive Autonomous Complex IV Activity in Autism Spectrum Disorder and Control Fibroblasts. 5th Annual Metabolic Health Summit 5/5 – 8, 2022, Santa Barbara, CA.
- Werner BA, Singh IN, Scheck AC, Lane AL, McCarty PJ, McLees S, Burrows BT, Brown D, Wilfong A, Adelson PD, Frye RE. Mitochondrial Dysfunctional in Neurological Disorders from Fresh Human Brain. 5th Annual Metabolic Health Summit 5/5 – 8, 2022, Santa Barbara, CA.
- Werner BA, Singh IN, Scheck AC, Lane AL, McCarty PJ, McLees S, Burrows BT, Brown D, Wilfong A, Adelson PD, Frye RE. Mitochondrial Respiration Alterations in Epileptic Foci from Fresh Human Brain. 5th Annual Metabolic Health Summit 5/5 – 8, 2022, Santa Barbara, CA.
- Sheets R, Werner BA, Perryman RA, Almekkawi AK, Singh IN, Frye RE, Syed N, Scheck AC. Mitochondrial and Gene Expression Changes in Brain Tumor Cells Grown in β -Hydroxybutyrate. 5th Annual Metabolic Health Summit 5/5 – 8, 2022, Santa Barbara, CA.
- Almekkawi AK, Sheets R, Werner BA, Perryman R, Singh IN, Karim M, Frye RE, Syed N, Scheck AC. Mitochondrial and Gene Expression Changes in Brain Tumor Cells Grown in B-Hydroxybutyrate. Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii266.

Peer-Reviewed Papers

1. Scheck AC and Landau JV. The effect of high hydrostatic pressure on eukaryotic protein synthesis. *Biochimica et Biophysica Acta*, 698: 149-157, 1982.
2. Wigdahl BL, Scheck AC, DeClercq E and Rapp F. High efficiency latency and activation of herpes simplex virus in human cells. *Science*, 217: 1145-1146, 1982.
3. Scheck AC and Landau JV. Stability of reticulocyte polysomes at high hydrostatic pressure. *Biochimica et Biophysica Acta*, 699: 226-231, 1982.
4. Wigdahl B, Scheck AC, Ziegler RJ, DeClercq E and Rapp F. Analysis of the herpes simplex virus genome during in vitro latency in human diploid fibroblasts and rat sensory neurons. *J. Virology*, 49: 205-213, 1984.
5. Scheck AC, Wigdahl B, DeClercq E and Rapp F. Prolonged HSV latency after treatment of infected cells with acyclovir and human leukocyte interferon. *Antimicrobial Agents and Chemotherapy*, 29: 589-593, 1986.
6. Scheck AC, Wigdahl B and Rapp F. Activation of latent herpes simplex virus type 2 infection in vitro requires a (E)- 5-(2-Bromovinyl)-2'-Deoxyuridine-sensitive gene function. *Intervirology*, 27: 121-129, 1987.
7. Scheck AC, Wigdahl B and Rapp F. Transcription of the herpes simplex virus genome during establishment, maintenance and reactivation of in vitro virus latency. *Intervirology*, 30:121-136, 1989.
8. Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AC, and Cleary P. The brain in AIDS: Central nervous system HIV-1 infection and AIDS dementia complex. *Science*, 239: 586-592, 1988.

9. Kong X-B, Scheck AC, Price RW, Vidal PM, Fanucchi MP, Watanabe KA, Fox JJ, and Chou T-C. Incorporation and metabolism of 2'-Fluoro-5-substituted arabinosyl pyrimidines, and their selective inhibition of viral DNA synthesis in herpes simplex virus type 1 (HSV-1)-infected and mock-infected vero cells. *Antiviral Res.* 10: 153-166, 1988.
10. Rosenblum M, Scheck AC, Cronin K, Brew BJ, Khan A, Paul M, and Price RW. Dissociation of AIDS-related vacuolar myelopathy (VM) and productive human immunodeficiency virus type 1 (HIV-1) infection of the spinal cord. *Neurology*, 39(7):892-6.
11. Shapiro JR, Mehta BM, Ebrahim SA, Scheck AC, Moots PL, Fiola MR. Tumor heterogeneity and intrinsically chemoresistant subpopulations in freshly resected human malignant gliomas. *Basic Life Sci* 1991;57:243-61.
12. Scheck AC, Mehta BM, Beikman MK, and Shapiro JR. BCNU-resistant human glioma cells with over-representation of chromosomes 7 and 22 demonstrate increased copy number and expression of platelet-derived growth factor genes. *Genes, Chromosomes and Cancer*, 8: 137-148, 1993.
13. Scheck AC. and Coons SW. Expression of the tumor suppressor gene in *DCC* in human gliomas. *Cancer Research* 53:5605-5609, 1993.
14. Scheck AC, Shapiro JR, Coons SW, Norman SA and Johnson PC. Biological and molecular analysis of low grade recurrence of glioblastoma multiforme. *Clinical Cancer Research* 2:187-199, 1996.
15. Golfinos JG, Norman SA, Coons SW, Norman R, Ballecer C and Scheck AC. Expression of the genes encoding myelin basic protein and proteolipid protein in gliomas. *Clinical Cancer Research* 3:799-804, 1997
16. Norman SA, Golfinos JG, and Scheck AC. Expression of a receptor protein tyrosine phosphatase in human glial tumors. *J. Neuro-Onc.* 36:209-217, 1998.
17. Norman SA, Rhodes SN, Treasurywala S, Hoelzinger DB, Shapiro JR and Scheck AC. Identification of transforming growth factor- β 1 binding protein overexpression in carmustine-resistant glioma cells by differential mRNA display. *Cancer*, 89:850-862, 2000.
18. Ivanov AI, Pero RS, Scheck AC, and Romanovsky AA. Prostaglandin E_2 -synthesizing enzymes in lipopolysaccharide fever: Differential transcriptional regulation at different febrile phases. *Am J Physiol Regul Integr Comp Physiol.* 283(5):R1104-17, 2002.
19. Ivanov AI, Scheck AC, and Romanovsky AA. Expression of genes controlling transport and catabolism of prostaglandin E_2 in lipopolysaccharide fever. (Epub 2002) *Am J Physiol Regul Integr Comp Physiol.* 284(3):R698-706, 2003.
20. Pfisterer WK, Hank NC, Preul MC, Hendricks W, Pueschel J, Coons SW and Scheck AC. Diagnostic and Prognostic Significance of Genetic Regional Heterogeneity in Meningiomas. *Neuro-Oncology*, 6(4):290-299, 2004.
21. Ivanov AI, Steiner AA, Scheck AC, and Romanovsky AA. Expression of Eph receptors and their ligands, ephrins, during lipopolysaccharide fever in rats. *Physiol Genomics* 21:152-160, 2005.
22. Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harch GR, Vogel H, Recht LD, Scheck AC and Sikic BI. TNFAIP3 as a putative regulator of NF- κ B-mediated resistance to O^6 -alkylating agents in human glioblastomas. *Journal of Clinical Oncology*, 24(2): 274-287, 2006.
23. Hank NC, Shapiro JR and Scheck AC. Over-Representation of Specific Regions of Chromosome 22 in Cells from Human Glioma Correlate with Resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea. (E-pub of .pdf) *BMC Cancer* 6:2, 2006.
24. Laskus T, Radkowski M, Adair DM, Wilkinson J, Scheck AC and Rakel J. Emerging evidence of hepatitis C virus neuroinvasion. *AIDS*, Oct;19 Suppl 3:S140-4, 2005.
25. Scheck AC, Perry K, Hank NC and Clark WD. Anticancer Activity of Extracts Derived from the Mature Roots of *Scutellaria Baicalensis* on Human Malignant Brain Tumor Cells. *BMC Complementary and Alternative Medicine*, 2006, 6:27 (16 August 2006)
26. Pfisterer WK, Hendricks WP, Scheck AC, Nieman RA, Birkner TH, Krampla WW, and Preul MC. Fluorescent in situ hybridization and ex vivo 1H MR spectroscopic examinations of meningioma tumor tissue: Is it possible to identify a clinically-aggressive subset of benign meningiomas? *Neurosurgery*. 2007 Nov;61(5):1048-59; discussion 1060-1.

27. Horvath S, Zhang B, Carlson M, Lu KV, Zhu S, Felciano RM, Laurance MF, Zhao W, Shu Q, Lee Y, Scheck AC, Liao LM, Wu H, Geschwind DH, Febbo PG, Kornblum HI, Cloughesy TF, Nelson SF and Mischel PS. Analysis of Oncogenic Signaling Networks in Glioblastoma Identifies ASPM as a Novel Molecular Target. *Proc Natl Acad Sci U S A*. 2006 Nov 14;103(46):17402-7. Epub 2006 Nov 7.
28. Pfisterer WK, Coons SW, Aboul-Enein A, Hendricks WP, Scheck AC* and Preul MC*. Implicating chromosomal aberrations with meningioma growth and recurrence: results from FISH and MIB-I analysis of grades I and II meningioma tissue. *J. Neuro-Oncology*, 2008 87(1): 43-50. Epub 2007 Nov 30. * = equal contribution as senior authors
29. Lee Y, Scheck AC, Cloughesy TF, Lai A, Farooqi HK, Coons S, Liao LM, Horvath S, Mischel, PS, Nelson, SF Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. *BMC Medical Genomics* 2008, 1:52 doi: 10.1186/1755-8794-1-52.
30. Smith KA, Ashby LS, Gonzalez F, Brachman DG, Thomas T, Coons SW, Battaglia M, Scheck AC. Prospective trial of gross total resection with Gliadel(R)wafers followed by early post-operative Gamma Knife(R)radiosurgery and conformal fractionated radiotherapy as initial treatment for patients with radiographically suspected newly diagnosed glioblastoma multiforme. *Journal of Neurosurgery (Suppl)* 109:106–117, 2008.
31. Scheck AC, Hendricks W. Molecular biological determinants of meningioma progression and aggressive behavior *Frontiers in Bioscience* E1, 390-414, June 1, 2009.
32. Steiner AA, Hunter JC, Phipps SM, Nucci TB, Oliveira DL, Roberts JL, Scheck AC, Simmons DL, Romanovsky AA. Cyclooxygenase-1 or -2: which one mediates lipopolysaccharide-induced hypothermia? *Am J Physiol Regul Integr Comp Physiol*. 297(2):R485-94, 2009. [Epub ahead of print Jun 10]
33. Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, Renfrow JJ, Yadav AK, Vogel H, Scheck AC, Tibshirani R, Sikic BI. A Network Model of a Cooperative Genetic Landscape in Brain Tumors. *JAMA*. 302(3):276-89, 2009.
34. Yadav AK, Renfrow JJ, Scholtens DM, Xie H, Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe PA, Das S, Scheck AC, Kessler JA, Soares MB, Sikic BI, Harsh GR, Bredel M. Monosomy of Chromosome 10 Associated with Dysregulation of Epidermal Growth Factor Signaling in Glioblastomas. *JAMA*. 302(3):261-75, 2009.
35. Sankar T, Delaney PM, Ryan RW, Eschbacher J, Abdelwahab M, Nakaji P, Coons SW, Scheck AC, Smith KA, Spetzler RF, Preul MC. Miniaturized handheld confocal microscopy for neurosurgery: results in an experimental glioblastoma model. *Neurosurgery*, 66(2): 410-8; discussion 417-8, 2010.
36. Pfisterer WK, Nieman RA, Scheck AC, Coons SW, Spetzler RF, Preul MC Using *ex vivo* proton magnetic resonance spectroscopy to reveal associations between biochemical and biological features of meningiomas. *Neurosurgical Focus* 28(1):E12, 2010.
37. Smith R, Smith K, Biggs C, Scheck AC. *In vitro* biologic dosimeter modeling of the glioblastoma response to radiation delivered by the Gamma Knife: Laboratory Investigation. *J Neurosurg*. 2010 Dec;113 Suppl:222-7 and *J Neurosurg*. Oct 2011: 15 (4) Collections:222-7.
38. Stafford P, Abdelwahab MG, Kim DY, Preul MA, Rho JM, Scheck AC. The Ketogenic Diet Reverses Gene Expression Patterns and Reduces Reactive Oxygen Species Levels When Used as an Adjuvant Therapy for Glioma. *Nutrition & Metabolism* 7 (1):74, 2010. [Epub ahead of print]
39. Bredel M, Yadav AK, Renfrow JJ, Scholtens DM, Chandler JP, Bredel C, Alvarez A, Lin D, Phillips HS, Tagge MJ, Lukac PJ, Robe PA, Vogel H, Dubner S, Mobley B, He X, Scheck AC, Sikic BI, Aldape KD, Chakravarti A, Harsh GR. *NFKB1A* Deletion in Malignant Gliomas. *N Engl J Med*. *N Engl J Med*. 2011 Feb 17;364(7):627-37. Epub 2010 Dec 22. (Editor's Choice - *Sci Transl Med* 2 March 2011: Vol. 3, Issue 72, p. 72ec28 DOI: 10.1126/scitranslmed.3002294 CANCER Toward the Future of Personalized Medicine Richard J. Lin)
40. Stuart JE, Lusk EA, Scheck AC, Coons SW, Lal A, Perry A, Gutmann DH. Identification of Gene Markers Associated with Aggressive Meningioma by Filtering Across Multiple Sets of Gene Expression Arrays. *J Neuropathol Exp Neurol*. 2011 70(1):1-12.

41. Myers CE, Hanavan P, Antwi K, Mahadevan D, Nadeem AJ, Cooke L, Scheck AC, Lake DF. CTL Recognition of a Novel HLA-A*0201-binding Peptide Derived from Glioblastoma Multiforme Tumor Cells. *Cancer Immunol Immunother*, 60(9):1319-1332, 2011 May 29 (Epub ahead of print).
42. Renfrow JJ, Scheck AC, Dhawan NS, Lukac PJ, Vogel H, Chandler JP, Raizer JJ, Harsh GR, Chakravarti A, Bredel M. Gene–protein correlation in single cells. *Neuro-Oncology* 13(8): 880-885, 2011. Cover article.
43. Martirosyan NL, Cavalcanti DD, Eschbacher JM, Delaney PM, Scheck AC, Abdelwahab MG, Nakaji PN, Spetzler RF, Preul MC. Use of *in Vivo* Near-infrared Laser Confocal Endomicroscopy with Indocyanine Green to Detect the Boundary of Infiltrative Tumor: Laboratory Investigation. *Journal of Neurosurgery* 115(6): 1131-1138, 2011.
44. Abdelwahab MG, Sankar T, Preul MC, Scheck AC. Intracranial Implantation with Subsequent *In Vivo* Bioluminescent Imaging of Murine Gliomas. *J. Vis. Exp.* (57), e3403, DOI: 10.3791/3403, 2011.
45. Scheck AC, Abdelwahab MG, Fenton K, Stafford P. The Ketogenic Diet for the Treatment of Glioma: Insights from Genetic Profiling. *Epilepsy Research*, 100: 327-337, 2012. Oct 21, 2011 epub ahead of print.
46. Abdelwahab MG, Fenton KE, Preul MC, Rho JM, Lynch A, Stafford P, Scheck AC. The Ketogenic Diet is an Effective Adjuvant to Radiation Therapy for the Treatment of Malignant Glioma. *PLoS ONE* 7(5): e36197. doi:10.1371/journal.pone.0036197, 2012.
47. Sankar T, Moore NZ, Johnson J, Ashby LS, Scheck AC, Shapiro WR, Smith KA, Spetzler RF, Preul MC. Magnetic Resonance Imaging volumetric assessment of the extent of contrast enhancement and resection in oligodendroglial tumors. *Journal of Neurosurgery*, 116(6):1172-1181, 2012. Epub ahead of print Editorial and AANS podcast will be included with this article.
48. Hughes A, Scheck AC, Coons SW, Stafford P, Johnston SA. Immunosignaturing can detect products from molecular markers in brain cancer, *PLoS ONE* 7(7): e40201. doi:10.1371/journal.pone. 0040201, 2012.
49. Kushchayev SV, Sankar T, Eggink LL, Kushchayeva YS, Wiener PC, Hooper JK, Eschbacher J, Liu R, Shi FD, Abdelwahab M, Scheck AC, Preul MC. Monocyte Galactose/N-acetylgalactosamine-specific C-type Lectin Receptor Stimulant Immunotherapy of an Experimental Glioma Part I: Stimulatory Effects on Monocyte-Derived Cells of the Brain and Tumor Growth, *Cancer Management and Research*, *Cancer Management and Research* 4 309–323, 2012.
50. Kushchayev SV, Sankar T, Eggink LL, Kushchayeva YS, Wiener PC, Hooper JK, Eschbacher J, Liu R, Shi FD, Abdelwahab M, Scheck AC, Preul MC. Monocyte Galactose/N-acetylgalactosamine-specific C-type Lectin Receptor Stimulant Immunotherapy of an Experimental Glioma: Part II: Combination with external radiation improves survival, *Cancer Management and Research* 4 325–334, 2012.
51. Kushchayev SV, Kushchayeva YS, Wiener PC, Scheck AC, Badie B, Preul MC. Monocyte-Derived Cells of the Brain and Malignant Gliomas: The Double Face of Janus. *World Neurosurg.* 2012 Nov 23. pii: S1878-8750(12)01358-7. doi: 10.1016/j.wneu.2012.11.059. [Epub ahead of print]
52. Fenton K, Martirosyan NL, Abdelwahab MG, Coons SW, Preul MC, Scheck AC. *In vivo* visualization of GL261-luc2 mouse glioma cells using Alexa Fluor® labeled Trp-2 antibody, *Journal of Neurosurgical Focus*, 36(2):E12, 2014.
53. Martirosyan NL, Georges J, Eschbacher JM, Cavalcanti DD, Elhadi AM, Abdelwahab MG, Scheck AC, Nakaji P, Spetzler RF, Preul MC. Potential application of a handheld confocal endomicroscope imaging system using a variety of fluorophores in experimental gliomas and normal brain. *Journal of Neurosurgical Focus*, 36(2):E16, 2014.
54. Woolf EC, Scheck AC. The Ketogenic Diet for the Treatment of Malignant Gliomas. *J Lipid Res.* 56(1):5-10, 2015. Feb 6 2014. Epub ahead of print
55. Woolf EC, Curley KL, Liu Q, Turner GH, Charlton JA, Preul MC, Scheck AC. The Ketogenic Diet Alters the Hypoxic Response and Effects Downstream Processes Involved in Angiogenesis,

- Invasion and Vascular Permeability in Glioma. PLoS ONE 10(6): e0130357. doi:10.1371/journal.pone.0130357, 2015.
56. Dardis C, Woolf EC and Scheck AC. A tool for reproducible research: From data analysis (in R) to a typeset laboratory notebook (as .pdf) using the text editor Emacs with the 'mp' package *F1000Research* 2016, 4:483 (doi: [10.12688/f1000research.6800.2](https://doi.org/10.12688/f1000research.6800.2))
 57. Lussier DM, Woolf EC, Brooks KS, Johnson JL, Blattman JN, Scheck AC. Enhanced immunity in a malignant glioma model is mediated by a therapeutic ketogenic diet. *BMC Cancer*, 16:310, 2016. DOI: 10.1186/s12885-016-2337-7 URL: <http://www.biomedcentral.com/1471-2407/16/310> 59.
 58. Rutter EM, Stepien TL, Anderies BJ, Plasencia JD, Woolf EC, Scheck AC, Turner GH, Liu Q, Frakes D, Kodibagkar V, Kuang Y, Preul MC, Kostelich EJ. Mathematical Analysis of Glioma Growth in a Murine Model. *Scientific Reports* 7(1) 2508, 2017. (doi: [9405510200864501672496](https://doi.org/10.1038/s41598-017-02508-2))
 59. Crain ID, Elias PS, Chapple K, Scheck AC, Karis JP, Preul MC. Improving the utility of 1H-MRS for the differentiation of glioma recurrence from radiation necrosis. *J Neurooncol.* 133(1):97-105, 2017. (doi: 10.1007/s11060-017-2407-y. Epub 2017 May 29. PMID:28555423)
 60. Belykh E, Miller EJ, Hu D, Martirosyan NL, Woolf EC, Scheck AC, Byvaltsev VA, Nakaji P, Nelson LY, Seibel EJ, Preul MC. Scanning fiber endoscope improves detection of 5-ALA induced protoporphyrin IX fluorescence at the boundary of infiltrative glioma. *World Neurosurgery*, 113:e51-e69, 2018. <https://doi.org/10.1016/j.wneu.2018.01.151>
 61. Belykh E, Patel AA, Miller EJ, Bozkurt B, Yagmurlu K, Woolf EC, Scheck AC, Eschbacher JM, Nakaji P, Preul MC. Probe-based 3-dimensional confocal laser endomicroscopy of brain tumors: Technical note, *Cancer Management and Research*, 10:3109-3123, 2018. PMID: 30214304 doi: 10.2147/CMAR.S165980.
 62. Belykh E, Miller EJ, Crotenuto A, Patel AA, Cavallo C, Martirosyan NL, Healey DR, Byvaltsev VA, Scheck AC, Lawton MT, Eschbacher JM, Nakaji P, Preul MC. Progress in Confocal Laser Endomicroscopy for Neurosurgery and Technical Nuances for Brain Tumor Imaging With Fluorescein. *Front. Oncol.*, 03 July 2019 | <https://doi.org/10.3389/fonc.2019.00554>.
 63. Georges J, Qi X, Liu X, Zhou Y, Woolf EC, Valeri A, Al-Atrache Z, Belykh E, Feuerstein BG, Preul M, Scheck AC, Reiser M, Anderson T, Gopez J, Appelt D, Yocom S, Eschbacher J, Yan H, Nakaji P. Provision of rapid and specific ex vivo diagnosis of central nervous system lymphoma from rodent xenograft biopsies by a fluorescent aptamer. *J Neurosurg.* Jul 24;134(6):1783-1790, 2020. doi: 10.3171/2020.4.JNS192476.
 64. Cash T, Fox E, Liu X, Minard CG, Reid JM, Scheck AC, Weigel BJ, Wetmore C. A Phase 1 Study of Prexasertib (LY2606368), a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors: A Report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADV1515). 2021 Sep;68(9):e29065. doi: 10.1002/psc.29065. Epub 2021 Apr 21.
 65. Belykh E, Jubran JH, George LL, Bardanova L, Healey DR, Georges JF, Quarles CC, Eschbacher JM, Mehta S, Scheck AC, Nakaji P, Preul MC. Molecular Imaging of Glucose Metabolism for Intraoperative Fluorescence Guidance During Glioma Surgery. *Mol Imaging Biol.* Aug;23(4):586-596, 2021.
 66. Hajji N, Garcia-Revilla J, Soto MS, Perryman R, Symington J, Quarles CC, Healey DR, Guo Y, Orta-Vázquez ML, Mateos-Cordero S, Shah K, Bomalaski J, Anichini G, Tzakos AG, Crook T, O'Neill K, Scheck AC, Venero JL, Syed N. Arginine deprivation alters microglial polarity and synergizes with radiation to eradicate non-arginine-auxotrophic glioblastoma tumors. *J Clin Invest.* Mar 15;132(6):e142137, 2022. doi: 10.1172/JCI142137.
 67. Voinsky I, Zoabi Y, Shomron N, Harel M, Cassuto H, Tam J, Rose S, Scheck AC, Karim MA, Frye RE, Aran A, Gurwitz D. Blood RNA Sequencing Indicates Upregulated BATF2 and LY6E and Downregulated ISG15 and MT2A Expression in Children with Autism Spectrum Disorder. *Int J Mol Sci.* 2022 Aug 30;23(17):9843. doi: 10.3390/ijms23179843.
 68. Almekkawi AK, AlJardali MW, Daadaa HM, Lane AL, Worner AR, Karim MA, Scheck AC, Frye RE. Folate Pathway Gene Single Nucleotide Polymorphisms and Neural Tube Defects: A Systematic Review and Meta-Analysis. *J Pers Med.* Sep 29;12(10):1609, 2022. doi: 10.3390/jpm12101609.

69. Frye RE, Lane A, Worner A, Werner BA, McCarty PJ, Scheck AC, Collins HL, Adelman SJ, Quadros EV, Rossignol DA. The Soluble Folate Receptor in Autism Spectrum Disorder: Relation to Autism Severity and Leucovorin Treatment. *J Pers Med*. 2022 Dec 8;12(12):2033. doi: 10.3390/jpm12122033.

Book Chapters and Solicited Articles

- Wigdahl B, Scheck AC, Smith CA, DeClercq E and Rapp F. Herpes simplex virus latency and reactivation: Design and analysis of *in vitro* constructs. In *Herpesvirus*, (Ed. F. Rapp), Alan R. Liss, Inc., New York, NY, Vol 21, pp. 227-238, 1984.
- Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AC and Cleary P. The brain in AIDS: Central nervous system HIV-1 infection and AIDS dementia complex. In: *AIDS 1988: AAAS Symposia Papers*. 1988.
- Shapiro JR, Mehta BM, Ebrahim SAD, Scheck AC, Moots PL and Fiola MR. Intrinsically chemoresistant subpopulations in freshly resected human malignant gliomas. In: *The Boundaries Between Promotion and Progression during Carcinogenesis* (L.A. Liotta, O. Sudilovsky, (eds.), New York: Plenum, pp243-262, 1991.
- Shapiro JR and Scheck AC. Molecular biological events in the selection of chemotherapy resistant-cells in human malignant gliomas. In: *Proceeding of the 15th International Symposium on Advances in Neuro-Oncology*. K. Takakura, M.D. Walker, P. Paolletti, (eds.), Amsterdam, The Netherlands: Kluwer Academic Pub., pp 21-26, 1991.
- Shapiro JR and Scheck AC Brain Tumors. In: *Cytogenetic Markers of Human Cancer*, S.R. Wolman and S. Sell (eds.), The Humana Press, Inc., 1997.
- Scheck AC. Molecular Biology of Chemotherapy and Resistance. *BNI Quarterly*, 14(2):43-53, 1998.
- Scheck AC. Chemotherapy Resistance. In: *Handbook of Brain Tumor Chemotherapy*. H. Newton (ed), San Diego, CA, Elsevier Inc. 2006.
- Scheck AC and Stafford P. Design and Use of Biomarkers for the Current and Future Clinical Management of Brain Tumors. *Biomarkers in Medicine*, 6(3):293-295, 2012.
- Woolf EC and Scheck AC. Metabolism and Glioma Therapy. *CNS Oncology*, 1(1): 7-10, 2012.
- Woolf EC and Scheck AC, The Ketogenic Diet for the Adjuvant Treatment of Malignant Brain Tumors In: *Bioactive Nutraceuticals and Dietary Supplements in Neurological and Brain Disease*, 1st Edition, Watson & Preedy (eds), Waltham, MA, Academic Press, Chapter 16, 2014.
- Scheck AC. Metabolism of Cancer Cells In: *Defy & Conquer*, Balcony 7 Media and Publishing, Pasadena, CA, By Mindy Elwell with JZ Bingham, 2015.
- Scheck AC. foreword to *Defy & Conquer*, Balcony 7 Media and Publishing, Pasadena, CA, By Mindy Elwell with JZ Bingham, 2015.
- Brooks KS, Woolf EC, Scheck AC. The ketogenic diet as an adjuvant therapy for brain tumors and other cancers In: *Critical Dietary Factors in Cancer Chemoprevention*, Springer International Publishing AG, Ullah & Ahmad (eds), 2015.
- Scheck AC and Woolf EC. The science behind a therapeutic ketogenic diet for brain tumors. *IBTA Magazine*, World edition, pp 48-49, 2016/2017.
- Scheck AC. expert opinion In: *The Ketogenic Kitchen*, Gill & Macmillan Ltd, Dublin, Ireland, By Domini Kemp and Patricia Daly, 2016.
- Woolf EC and Scheck AC. Ketogenic diet as adjunctive therapy for malignant brain cancer. *Ketogenic Diet and Metabolic Therapies: Expanded Roles in Health and Disease*. Ed: Masino SA, Kossoff EH, Boison D, D'Agostino DP and Rho, JM. New York: Oxford UP, 2017.
- Woolf EC, Syed N, Scheck AC. Tumor Metabolism, the Ketogenic Diet and β -Hydroxybutyrate: Novel Approaches to Adjuvant Brain Tumor Therapy. *Front Mol Neurosci*. Nov 16;9:122, 2016.
- Scheck AC. Review on the Treatment of Brain Tumour at the Global Symposium. Matthew's Friends Ketogenic Therapies Autumn/Winter Newsletter pg 4-5, 2016.

- Klement RJ, Feinman RD, Gross EC, Champ CE, D'Agostino D, Fine EJ, Kämmerer U, Poff A, Rho JM, Seyfried TN, Scheck AC. Need for revised review of article on ketogenic dietary regimes for cancer. Medical Oncology, 2017 Jun;34(6):108. doi: 10.1007/s12032-017-0968-4. Epub 2017 Apr 27.
- Scheck AC. The role of metabolic ketosis as adjuvant therapy for brain tumors. Expert Opinion, Neurodiem, Nov 19, 2019.
- Scheck AC and Syed N. Ketogenic diet as adjunctive therapy for malignant brain cancer. In: Masino SA, Boison D, D'Agostino DP, Kossoff EH, Rho JM (Eds). Ketogenic Diet and Metabolic Therapies: Expanded Roles in Health and Disease, 2nd Edition, Oxford University Press, 2022.

On-line presentations/interviews/documentary movies

- 2012 (posted on Yumpu 2013) Perkin Elmer User's Group invited talk
<https://www.yumpu.com/en/document/view/23044588/the-ketogenic-diet-adrienne-c-scheck-phd-perkinelmer>
- 8/7/13 [Dr. Adrienne C. Scheck, Ph.D. is recognized by Continental Who's Who as a Pinnacle Professional \(prnewswire.com\)](https://www.prnewswire.com)
- 2014 Matthew's Friends Symposium talk <https://www.youtube.com/watch?v=F3VQIWWdtiw>
- 2014 Matthew's Friends Symposium interview <https://www.youtube.com/watch?v=l-r-K7yXI64>
- 11/4/14 labroots <https://www.youtube.com/watch?v=xBy3yIqjMw>
- 3/1/16 podcast <http://metabolicoptimization.com/index.php/podcasts/76-episode-3>
- 6/15/16 2nd Annual Conference on Nutritional Ketosis and Metabolic Therapeutics talk
www.youtube.com/watch?v=vMOhFmY8S-Q.
- 10/20/16 Interviews by the Charlie Foundation <https://www.youtube.com/watch?v=Upqq4H5nIXs>;
<https://www.youtube.com/watch?v=yFFFwlfzbTM>
- 11/25/16 <http://www.nourishbalancethrive.com/podcasts/nourish-balance-thrive/new-hope-brain-tumors/> downloaded over 42,635 times
- 2016 The Ketogenic Kitchen [Adrienne C. Scheck - PhD - The Ketogenic Kitchen](https://www.youtube.com/watch?v=SZzefkldSfg)
- 7/16/17 Keto MasterClass, HealthMasters Live "Ketogenic Metabolic Therapy for Brain Tumors: Fighting the Perfect Storm"
- 2018 [Foundation For Metabolic Cancer Therapies - Home](https://www.foundationfor-metabolic-cancer.org/) [Foundation For Metabolic Cancer Therapies - Fighting Cancer with Fats](https://www.foundationfor-metabolic-cancer.org/therapies-fighting-cancer-with-fats)
- 2/16/21 "Metabolic Therapies for Malignant Brain Tumors"
www.youtube.com/watch?v=SZzefkldSfg
- 3/10/21 Finding Genius Podcast "Could the Ketogenic Diet Impact Every Hallmark of Cancer?"
Posted on Finding Genius Website, iTunes (Apple Podcasts), YouTube, Podcast Addict, Spotify, iHeart Radio, Castbox, Stitcher, Google Podcast, Amazon Music, Audible
- 2021 "Cancerevolution" Documentary film <https://cancerevolution.film/news/CANCER/EVOLUTION> | [Adrienne C. Scheck, PhD \(cancerevolution.film\)](https://cancerevolution.film)

Articles, TV, Radio I am quoted in or interviewed for

- 2/17/16 "Ketogenic diet's reputed anticancer credentials put to test"
<https://www.newscientist.com/article/2078558-ketogenic-diets-reputed-anticancer-credentials-put-to-test/>
- Spring 2016 "A 'one-two punch' to cancer" Optimum Nutrition magazine, The Institute for Optimum Nutrition, United Kingdom

4/10/16 CTV News “Scientists studying effect of ketogenic diet on brain cancer”
<http://www.ctvnews.ca/health/scientists-studying-effect-of-ketogenic-diet-on-brain-cancer-1.2853439>

Aaron Rand, CJAD 800 AM drive show, Montreal, Canada – radio interview

7/5/16 Cancer, Carbs and Controversy, Brittney Saline CrossFit Journal
<http://journal.crossfit.com/2016/07/cancer-carbs-and-controversy.tpl#featureArticleTitl>

August 2016 <https://www.barrowneuro.org/researcher-profiles/barrow-program-provides-high-school-students-undergrads-with-lab-experience/>

August 2, 2016 Keto Advocate <https://www.youtube.com/watch?v=-GFFQ7zf0mY>

9/3/16 High school student spends her days on serious cancer research
http://www.eastvalleytribune.com/arizona/article_46973730-6e2d-11e6-a910-b37ddafca672.html#.V9BCyZuYiAQ.email

8/9/17 'I have a way to beat this thing.'

11/15/17 “What Inspires You?” <https://www.facebook.com/search/top/?q=brian%20underwood>

1/30/19 Can a keto diet treat brain cancer? By Anne Mullens

June 2019 What You Need to Know About the Keto Diet <https://experiencelife.com/article/what-you-need-to-know-about-keto-diet/> By Laine Bergeson Becco, FMCHC

7/27/19 OurBrainBank Voices chat
<https://www.youtube.com/watch?v=v0r1DV17cr0&feature=youtu.be>